Submitted:
31 August 2024
Posted:
03 September 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Mechanisms of Microvessels Formation. Angiogenic Growth Factors
3. Molecular Structures Influencing ECM Activity
Angiopoetin-1 and Angiopoetin-2 (ANG1 and ANG2)
Vascular Endothelial Growth Factor (VEGF)
Placental Growth Factor-2 (PlGF)
Human Telomerase Reverse Transcriptase (hTERT)
Fibroblast Growth Factor (FGF)
Hepatocyte Growth Factor (HGF)
Angiogenic Factor with G-Patch and Forkhead-Associated Domain 1 (AGGF1)
Thrombin
Interleukin Families
Interleukin -1 Beta (IL -1 β)
Interleukin -1 Alpha (IL -1 α)
Interleukin -4
Interleukin -5
Interleukin -6
Interleukin -7
Interleukin -8
Interleukin -9
Interleukin -10
Interleukin -11
Interleukin -12 Family
Interleukin -13
Interleukin -15
Interleukin -17
Interleukin -18
Interleukin -19
Interleukin -20
Interleukin -22
Interleukin -23
Interleukin -24
Interleukin -25
Interleukin -27
Interleukin -32
Interleukin -33
Interleukin -35
Interleukin -37
TNFα (Tumor Necrosis Factor-Alpha)
Interferon-α (INF-α)
Interferon -γ (IFN -γ)
Transforming Growth Factor-α (TGF-α)
Transforming Growth Factor-β (TGF-β)
Platelet-Derived Growth Factor- BB (PDGF-BB)
Matrix Metalloproteinases (MMP -2, MMP -9)
4. Remodeling of the Basement Membrane during Ischemia
5. Angiogenesis with the Combined Use of Growth Factors
Integrins
6. Atherogenic Inflammation in the Vascular Wall and Beyond It
6.1. Lipid Metabolic Disorders
6.2. Monocyte Transmobilization







6.3. T-Cells
6.4. B Cells
6.5. Platelets
6.6. Macrophages
6.7. Dendritic Cells
7. Angiogenic, Proatherogenic and Antiatherogenic Growth Factors in Atherosclerotic Lesions of the Vascular Wall
8. Cell Functions in a Soft Atherogenic Plaque with Hypercholesterolemia in the Intimate and Middle Zones of the Vascular Wall
8.1. Circulating Monocytes
8.2. Smooth Muscle Cells (VSMCS) and Residual Macrophages
9. Mechanisms of Regulation of Lipid Metabolism in the Vascular Wall in Case of Using Natural Polysaccharides. The Role of Growth Factors in the Regulation of Atherogenic Inflammation
10. Problems of Angiogenesis Activation
11. Effects of Endothelialization of Polysaccharide Matrices in Atherosclerosis. The Role of Sulfated Polysaccharide Derivatives










Conclusions
- Various methods have been developed to couple growth factors with natural or synthetic biomaterials and chemicals. These immobilized factors will be available to cells that come into contact with the matrix, providing a highly localized signal to control cell fate. In the case of active angiogenesis, growth factors can bind to the surfaces of the scaffolds, providing proangiogenic signals to the surrounding tissue. [683]. Injectable scaffolds are a promising approach to promote angiogenesis as they are less invasive than implantation of solid scaffolds and can contour to fill cavities [684,685] . Growth factors can be active in a bound state or activated as a result of detachment from the matrix. Site-specific binding of growth factors and other biological molecules allows control of multiple growth factor functions and their delivery. There are two main strategies for direct presentation of growth factors on external matrices: a) physical adsorption due to hydrogen bonding of proteins; b) covalent immobilization of growth factor or growth factor mimic molecules into a matrix (covalent approach). Regardless of which technique is used to immobilize growth factors, scaffolding also imparts to cells the ability to recruit functional proteins into intimate cell-cell contact.
- Increased activation of growth factor receptors, such as VEGF-A, B D GF or FGF-2, in the extracellular matrix is associated with the inclusion of integrin in the interaction chain. Chemical or physical modification of the surface of extracellular matrix substrates with heparin is used to bind growth factors through their affinity for grafted heparin. Heparin-based growth factor delivery systems have demonstrated the ability to provide sustained release of growth factors [686].
- Cell migration, determined through the integrin-growth factor receptor system signaling, can be activated by an electrostatic gradient in the presence of sulfated chitosan.
- High affinity adsorption of growth factors in the ECM to the implanted sulfated form of chitosan ensures the connection of growth factors with the ECM, and, therefore, stimulates unhindered diffusion to the surface of endothelial cells and cells of the mural zone. Provided that a growth factor adsorbed on the carrier, for example, VEGF, will be actively presented to endothelial cells at a low level of the Notch signal, the process of regional angiogenesis is expected to be high.
- When cells come into contact with the implanted chitosan polymer, physically immobilized and carrier-bound growth factors will be available to the cells, likely providing a highly localized signal to trigger cell function. In this case, the role of intermediate structures that perform the functions of opsonization of growth factors on the surface of the transfer system can be played by both sulfhydryl groups of the polymer itself and oligopeptides, fibronectin, collagen, elastin or the glycosaminoglycan family. Such a complex multicomponent growth factor delivery system can significantly increase the survival of endothelial cells and restore local blood perfusion in ischemic tissue [687].
- It is assumed that the polyanionic soluble form of sulfated chitosan, when implanted into the paravasal fascial sheath of the main vessel, will be non-toxic for growth factors adsorbed in the ECM. An important condition is the preservation of protein activity in the delivery system. The chitosan platform with a pH around 7 or slightly alkaline can modify the structure of the transport system, immobilize growth factors, increase the degradation time and release of growth factors into the ECM compared to many cationic polymers.
- It is possible that the introduction of a chitosan hydrogel with sulfhydryl groups into the paravasal space leads to the formation of affinity complexes with cholesterol as stable and monodisperse gelation platforms that include growth factors [688].
- The rate of degradation of the transport system probably depends on the concentration of the polysaccharide polymer [689]. It is assumed that changing the concentration of polysaccharides in tissues (implantation of sulfated chitosan into the paravasal zone of the main vessel) changes the dynamics of the release of growth factors from vascular endothelial cells, smooth muscle cells, other ECM cells, the regenerative profile of lymphocytes, and macrophages. In addition, implantation of a certain volume of polymer into the main vessel casing creates mechanical stress on the tissue. This exogenous factor stimulates the production or release of growth factors in the ECM and cell-cell contacts with activation through GFs receptors and integrin signaling pathways. The cell response manifests itself in the form of differentiation, proliferation and migration. The high affinity of polysaccharide polymers for cholesterol and LDL, active vascularization of ECM -2 provoke a gradient of cholesterol translation towards the hydrogel “shirt”, draining cells and lipids from the subintimal zone of ECM -1 to the ECM -2 zone. In addition, short chains of hydrolysis products of the polysaccharide implant fill not only ECM -2, but also diffuse back into ECM -1, binding to the cell surface of polymorphonuclear leukocytes and macrophages. It is assumed that such a supply of cholesterol from the subintimal zone can be combined not only with the translation of “foam” cells, but also of extracellular oxLDL , carried out of the membrane by the foam cells themselves using the ABCA1 and ABCG1 transporters. Cholesterol efflux plays an important role in antiatherogenesis, and manipulation of this process may provide a new therapeutic approach to great vessel pathology [690].
- There is an assumption that activation of efferocytosis with the help of polysaccharide matrices, which reduces the mass of apoptotic cells, can prevent secondary necrosis and inflammation, reduce the growth of necrotic nuclei [691]. Resorption and active drainage into position of a polymer having an electrostatic charge are aimed at restoring the integrity and function of tissues during inflammation. Switching the function of pro-inflammatory macrophages to an anti-inflammatory pool of cells using specific lipids [381] opens up the prospect of controlling the atherogenic process, especially at an early stage of development. Obtaining a mass of non-inflammatory macrophages in the wall of an arterial vessel is a very interesting project [692]. This process ends with local decholesterolization and restructuring of the mural zone of the vascular wall. Such processes in the wall of the main vessel change its morphology and function, which should be reflected in improved perfusion characteristics. Bringing a gel matrix to the zone of ischemia and dislocation of atherogenic plaques as an independent structure for contact with stationary ECM proteins, endogenous endothelial cells and cells of the mural zone to activate angiogenesis is considered an effective treatment regimen. This is due to the fact that more than 90% of the exogenous cell mass is eliminated within 24 hours after transplantation and after 4 weeks it is only 1% [693]. In connection with this postulate, it is necessary to pay special attention to the mechanisms of the antiatherogenic action of the adventitia of large arterial vessels.
- Developing mechanisms to improve the stability of encapsulated proteins and their release over time will require the efforts of researchers working in several disciplines, including chemical synthesis, experimental tissue engineering, pathology modeling, molecular biology and medicine.
Author Contributions
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflict of interests
References
- Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, Rudan I. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019, 7, 1020–1030. [Google Scholar] [CrossRef] [PubMed]
- Abu Dabrh AM, Steffen MW, Undavalli C, Asi N, Wang Z, Elamin MB, Conte MS, Murad MH. The natural history of untreated severe or critical limb ischemia. J Vasc Surg. 2015, 62, 1642–1651. [Google Scholar] [CrossRef] [PubMed]
- Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015, 116, 1509–1526. [Google Scholar] [CrossRef] [PubMed]
- Han J, Luo L, Marcelina O, Kasim V, Wu S. Therapeutic angiogenesis-based strategy for peripheral artery disease. Theranostics. 2022, 12, 5015–5033. [Google Scholar] [CrossRef]
- Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group; Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E 3rd, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007, 33, Suppl 1,S1–75. [Google Scholar] [CrossRef]
- O’Connor C, Brady E, Zheng Y, Moore E, Stevens KR. Engineering the multiscale complexity of vascular networks. Nat Rev Mater. 2022, 7, 702–716. [Google Scholar] [CrossRef]
- Khademhosseini A, Langer R. A decade of progress in tissue engineering. Nat Protoc. 2016, 11, 1775–1781. [Google Scholar] [CrossRef]
- Riley CM, Fuegy PW, Firpo MA, Shu XZ, Prestwich GD, Peattie RA. Stimulation of in vivo angiogenesis using dual growth factor-loaded crosslinked glycosaminoglycan hydrogels. Biomaterials. 2006, 27, 5935–5943. [Google Scholar] [CrossRef]
- Chiu LL, Radisic M. Scaffolds with covalently immobilized VEGF and Angiopoietin-1 for vascularization of engineered tissues. Biomaterials. 2010, 31, 226–241. [Google Scholar] [CrossRef]
- Layman H, Li X, Nagar E, Vial X, Pham SM, Andreopoulos FM. Enhanced angiogenic efficacy through controlled and sustained delivery of FGF-2 and G-CSF from fibrin hydrogels containing ionic-albumin microspheres. J Biomater Sci Polym Ed. 2012, 23, 185–206. [Google Scholar] [CrossRef]
- Roberts JJ, Farrugia BL, Green RA, Rnjak-Kovacina J, Martens PJ. In situ formation of poly(vinyl alcohol)-heparin hydrogels for mild encapsulation and prolonged release of basic fibroblast growth factor and vascular endothelial growth factor. J Tissue Eng. 2016, 7, 2041731416677132. [Google Scholar] [CrossRef] [PubMed]
- Zieris A, Chwalek K, Prokoph S, Levental KR, Welzel PB, Freudenberg U, Werner C. Dual independent delivery of pro-angiogenic growth factors from starPEG-heparin hydrogels. J Control Release. 2011, 156, 28–36. [Google Scholar] [CrossRef] [PubMed]
- Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000, 407, 242–248. [Google Scholar] [CrossRef] [PubMed]
- Li B, Xiu R. Angiogenesis: from molecular mechanisms to translational implications. Clin Hemorheol Microcirc. 2013, 54, 345–355. [Google Scholar] [CrossRef] [PubMed]
- Jansen PL, Rosch R, Jansen M, Binnebösel M, Junge K, Alfonso-Jaume A, Klinge U, Lovett DH, Mertens PR. Regulation of MMP-2 gene transcription in dermal wounds. J Invest Dermatol. 2007, 127, 1762–1767. [Google Scholar] [CrossRef]
- Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007, 7, 803–815. [Google Scholar] [CrossRef]
- Brudno Y, Ennett-Shepard AB, Chen RR, Aizenberg M, Mooney DJ. Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors. Biomaterials. 2013, 34, 9201–9209. [Google Scholar] [CrossRef]
- Rohlenova K, Veys K, Miranda-Santos I, De Bock K, Carmeliet P. Endothelial Cell Metabolism in Health and Disease. Trends Cell Biol. 2018, 28, 224–236. [Google Scholar] [CrossRef]
- Paku S, Dezso K, Bugyik E, Tóvári J, Tímár J, Nagy P, Laszlo V, Klepetko W, Döme B. A new mechanism for pillar formation during tumor-induced intussusceptive angiogenesis: inverse sprouting. Am J Pathol. 2011, 179, 1573–1585. [Google Scholar] [CrossRef]
- Betz C, Lenard A, Belting HG, Affolter M. Cell behaviors and dynamics during angiogenesis. Development. 2016, 143, 2249–2260. [Google Scholar] [CrossRef]
- Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykhozhij S, Peri F, Wilson SW, Ruhrberg C. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood. 2010, 116, 829–840. [Google Scholar] [CrossRef] [PubMed]
- Gianni-Barrera R, Bartolomeo M, Vollmar B, Djonov V, Banfi A. Split for the cure: VEGF, PDGF-BB and intussusception in therapeutic angiogenesis. Biochem Soc Trans. 2014, 42, 1637–1642. [Google Scholar] [CrossRef] [PubMed]
- Sivaraj KK, Adams RH. Blood vessel formation and function in bone. Development. 2016, 143, 2706–2715. [Google Scholar] [CrossRef] [PubMed]
- Li H, Chang J. Stimulation of proangiogenesis by calcium silicate bioactive ceramic. Acta Biomater. 2013, 9, 5379–5389. [Google Scholar] [CrossRef]
- Gorustovich AA, Roether JA, Boccaccini AR. Effect of bioactive glasses on angiogenesis: a review of in vitro and in vivo evidences. Tissue Eng Part B Rev. 2010, 16, 199–207. [Google Scholar] [CrossRef]
- Carmeliet, P. Angiogenesis in life, disease and medicine. Nature. 2005, 438, 932–936. [Google Scholar] [CrossRef]
- Davidson, SM. FAM3A - A mitochondrial route to the stimulation of angiogenesis? EBioMedicine. 2019, 43, 3–4. [Google Scholar] [CrossRef]
- Chapanian R, Amsden BG. Combined and sequential delivery of bioactive VEGF165 and HGF from poly(trimethylene carbonate) based photo-cross-linked elastomers. J Control Release. 2010, 143, 53–63. [CrossRef]
- Chen RR, Silva EA, Yuen WW, Brock AA, Fischbach C, Lin AS, Guldberg RE, Mooney DJ. Integrated approach to designing growth factor delivery systems. FASEB J. 2007, 21, 3896–3903. [Google Scholar] [CrossRef]
- Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, Cheresh DA. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008, 456, 809–813. [Google Scholar] [CrossRef]
- Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. 2013, 328, 18–26. [Google Scholar] [CrossRef] [PubMed]
- Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999, 286, 2511–2514. [CrossRef]
- Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007, 6, 273–286. [Google Scholar] [CrossRef] [PubMed]
- Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncology. 2011, 81, Suppl 1,24–29. [Google Scholar] [CrossRef]
- Payne LB, Tewari BP, Dunkenberger L, Bond S, Savelli A, Darden J, Zhao H, Willi C, Kanodia R, Gude R, Powell MD, Oestreich KJ, Sontheimer H, Dal-Pra S, Chappell JC. Pericyte Progenitor Coupling to the Emerging Endothelium During Vasculogenesis via Connexin 43. Arterioscler Thromb Vasc Biol. 2022, 42, 96–114. [CrossRef]
- Kruse K, Lee QS, Sun Y, Klomp J, Yang X, Huang F, Sun MY, Zhao S, Hong Z, Vogel SM, Shin JW, Leckband DE, Tai LM, Malik AB, Komarova YA. N-cadherin signaling via Trio assembles adherens junctions to restrict endothelial permeability. J Cell Biol. 2019, 218, 299–316. [Google Scholar] [CrossRef]
- Moccia F, Negri S, Shekha M, Faris P, Guerra G. Endothelial Ca2+ Signaling, Angiogenesis and Vasculogenesis: Just What It Takes to Make a Blood Vessel. Int J Mol Sci. 2019, 20, 3962. [Google Scholar] [CrossRef]
- Annex, BH. Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol. 2013, 10, 387–396. [Google Scholar] [CrossRef]
- Johnson KE, Wilgus TA. Vascular Endothelial Growth Factor and Angiogenesis in the Regulation of Cutaneous Wound Repair. Adv Wound Care (New Rochelle). 2014, 3, 647–661. [Google Scholar] [CrossRef]
- Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004, 56, 549–580. [Google Scholar] [CrossRef]
- Braghirolli DI, Helfer VE, Chagastelles PC, Dalberto TP, Gamba D, Pranke P. Electrospun scaffolds functionalized with heparin and vascular endothelial growth factor increase the proliferation of endothelial progenitor cells. Biomed Mater. 2017, 12, 025003. [Google Scholar] [CrossRef]
- Yoo SY, Kwon SM. Angiogenesis and its therapeutic opportunities. Mediators Inflamm. 2013, 2013, 127170. [Google Scholar] [CrossRef]
- Maharaj AS, Saint-Geniez M, Maldonado AE, D’Amore PA. Vascular endothelial growth factor localization in the adult. Am J Pathol. 2006, 168, 639–648. [Google Scholar] [CrossRef] [PubMed]
- Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer. 2010, 10, 505–514. [Google Scholar] [CrossRef]
- Cadenas, S. ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection. Free Radic Biol Med. 2018, 117, 76–89. [Google Scholar] [CrossRef]
- Kivelä R, Bry M, Robciuc MR, Räsänen M, Taavitsainen M, Silvola JM, Saraste A, Hulmi JJ, Anisimov A, Mäyränpää MI, Lindeman JH, Eklund L, Hellberg S, Hlushchuk R, Zhuang ZW, Simons M, Djonov V, Knuuti J, Mervaala E, Alitalo K. VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol Med. 2014, 6, 307–321. [Google Scholar] [CrossRef]
- Groppa E, Brkic S, Bovo E, Reginato S, Sacchi V, Di Maggio N, Muraro MG, Calabrese D, Heberer M, Gianni-Barrera R, Banfi A. VEGF dose regulates vascular stabilization through Semaphorin3A and the Neuropilin-1+ monocyte/TGF-β1 paracrine axis. EMBO Mol Med. 2015, 7, 1366–1384. [Google Scholar] [CrossRef]
- Grunewald M, Kumar S, Sharife H, Volinsky E, Gileles-Hillel A, Licht T, Permyakova A, Hinden L, Azar S, Friedmann Y, Kupetz P, Tzuberi R, Anisimov A, Alitalo K, Horwitz M, Leebhoff S, Khoma OZ, Hlushchuk R, Djonov V, Abramovitch R, Tam J, Keshet E. Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span. Science. 2021, 373, eabc8479. [Google Scholar] [CrossRef]
- Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholová I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K, Ylä-Herttuala S. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res. 2003, 92, 1098–1106. [Google Scholar] [CrossRef]
- Wu M, Pokreisz P, Swinnen M, Caluwe E, Gillijns H, Vanden Driessche N, Casazza A, Verbeken E, Collen D, Janssens S. Sustained Placental Growth Factor-2 Treatment Does Not Aggravate Advanced Atherosclerosis in Ischemic Cardiomyopathy. J Cardiovasc Transl Res. 2017, 10, 348–358. [Google Scholar] [CrossRef]
- Khurana R, Moons L, Shafi S, Luttun A, Collen D, Martin JF, Carmeliet P, Zachary IC. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation. 2005, 111, 2828–2836. [Google Scholar] [CrossRef] [PubMed]
- Murasawa S, Llevadot J, Silver M, Isner JM, Losordo DW, Asahara T. Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation. 2002, 106, 1133–1139. [Google Scholar] [CrossRef] [PubMed]
- Goonoo N, Bhaw-Luximon A. Mimicking growth factors: role of small molecule scaffold additives in promoting tissue regeneration and repair. RSC Adv. 2019, 9, 18124–18146. [Google Scholar] [CrossRef] [PubMed]
- Risau, W. Angiogenic growth factors. Prog Growth Factor Res. 1990, 2, 71–79. [Google Scholar] [CrossRef]
- Chung JC, Shum-Tim D. Neovascularization in tissue engineering. Cells. 2012, 1, 1246–1260. [Google Scholar] [CrossRef]
- Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011, 473, 298–307. [Google Scholar] [CrossRef]
- Zhao W, Han Q, Lin H, Gao Y, Sun W, Zhao Y, Wang B, Chen B, Xiao Z, Dai J. Improved neovascularization and wound repair by targeting human basic fibroblast growth factor (bFGF) to fibrin. J Mol Med (Berl). 2008, 86, 1127–1138. [Google Scholar] [CrossRef]
- Li J, Wei Y, Liu K, Yuan C, Tang Y, Quan Q, Chen P, Wang W, Hu H, Yang L. Synergistic effects of FGF-2 and PDGF-BB on angiogenesis and muscle regeneration in rabbit hindlimb ischemia model. Microvasc Res. 2010, 80, 10–17. [Google Scholar] [CrossRef]
- Nikol S, Baumgartner I, Van Belle E, Diehm C, Visoná A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Graham Wyatt M, Dinesh Wijesinghe L, Fusari M, Stephan D, Emmerich J, Pompilio G, Vermassen F, Pham E, Grek V, Coleman M, Meyer F. Therapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia. Mol Ther. 2008, 16, 972–978. [Google Scholar] [CrossRef]
- Cai S, Liu Y, Zheng Shu X, Prestwich GD. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials. 2005, 26, 6054–6067. [Google Scholar] [CrossRef]
- Oh JK, Drumright R, Siegwart D, Maty-jaszewski K. The Development of Microgels/Nanogels for Drug Delivery Applications. Prog Polym Sci. 2008, 33, 448–477. [Google Scholar] [CrossRef]
- Phan VH, Thambi T, Duong HT, Lee DS. Poly(amino carbonate urethane)-based biodegradable, temperature and pH-sensitive injectable hydrogels for sustained human growth hormone delivery. Sci Rep. 2016, 6, 29978. [Google Scholar] [CrossRef] [PubMed]
- Duan H, Li X, Wang C, Hao P, Song W, Li M, Zhao W, Gao Y, Yang Z. Functional hyaluronate collagen scaffolds induce NSCs differentiation into functional neurons in repairing the traumatic brain injury. Acta Biomater. 2016, 45, 182–195. [Google Scholar] [CrossRef] [PubMed]
- Xiang Q, Xiao J, Zhang H, Zhang X, Lu M, Zhang H, Su Z, Zhao W, Lin C, Huang Y, Li X. Preparation and characterisation of bFGF-encapsulated liposomes and evaluation of wound-healing activities in the rat. Burns. 2011, 37, 886–895. [Google Scholar] [CrossRef]
- Mukherjee S, Patra CR. Therapeutic application of anti-angiogenic nanomaterials in cancers. Nanoscale. 2016, 8, 12444–12470. [Google Scholar] [CrossRef]
- Powell RJ, Goodney P, Mendelsohn FO, Moen EK, Annex BH; HGF-0205 Trial Investigators. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg. 2010, 52, 1525–1530. [CrossRef]
- Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, Morishita R, Annex BH. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation. 2008, 118, 58–65. [Google Scholar] [CrossRef]
- Morishita R, Shimamura M, Takeya Y, Nakagami H, Chujo M, Ishihama T, Yamada E, Rakugi H. Combined Analysis of Clinical Data on HGF Gene Therapy to Treat Critical Limb Ischemia in Japan. Curr Gene Ther. 2020, 20, 25–35. [Google Scholar] [CrossRef]
- Sanada F, Fujikawa T, Shibata K, Taniyama Y, Rakugi H, Morishita R. Therapeutic Angiogenesis Using HGF Plasmid. Ann Vasc Dis. 2020, 13, 109–115. [Google Scholar] [CrossRef]
- Pyun WB, Hahn W, Kim DS, Yoo WS, Lee SD, Won JH, Rho BS, Park ZY, Kim JM, Kim S. Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Ther. 2010, 17, 1442–1452. [Google Scholar] [CrossRef]
- Lu Q, Yao Y, Yao Y, Liu S, Huang Y, Lu S, Bai Y, Zhou B, Xu Y, Li L, Wang N, Wang L, Zhang J, Cheng X, Qin G, Ma W, Xu C, Tu X, Wang Q. Angiogenic factor AGGF1 promotes therapeutic angiogenesis in a mouse limb ischemia model. PLoS One. 2012, 7, e46998. [Google Scholar] [CrossRef]
- Yao Y, Li Y, Song Q, Hu C, Xie W, Xu C, Chen Q, Wang QK. Angiogenic Factor AGGF1-Primed Endothelial Progenitor Cells Repair Vascular Defect in Diabetic Mice. Diabetes. 2019, 68, 1635–1648. [Google Scholar] [CrossRef] [PubMed]
- Wang J, Peng H, Timur AA, Pasupuleti V, Yao Y, Zhang T, You SA, Fan C, Yu Y, Jia X, Chen J, Xu C, Chen Q, Wang Q. Receptor and Molecular Mechanism of AGGF1 Signaling in Endothelial Cell Functions and Angiogenesis. Arterioscler Thromb Vasc Biol. 2021, 41, 2756–2769. [Google Scholar] [CrossRef]
- Wu J, Heemskerk JWM, Baaten CCFMJ. Platelet Membrane Receptor Proteolysis: Implications for Platelet Function. Front Cardiovasc Med. 2021, 7, 608391. [Google Scholar] [CrossRef]
- Heuberger DM, Schuepbach RA. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb J. 2019, 17, 4. [Google Scholar] [CrossRef]
- Posma JJ, Posthuma JJ, Spronk HM. Coagulation and non-coagulation effects of thrombin. J Thromb Haemost. 2016, 14, 1908–1916. [Google Scholar] [CrossRef]
- Posma JJ, Grover SP, Hisada Y, Owens AP 3rd, Antoniak S, Spronk HM, Mackman N. Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases. Arterioscler Thromb Vasc Biol. 2019, 39, 13–24. [Google Scholar] [CrossRef]
- Burzynski LC, Humphry M, Pyrillou K, Wiggins KA, Chan JNE, Figg N, Kitt LL, Summers C, Tatham KC, Martin PB, Bennett MR, Clarke MCH. The Coagulation and Immune Systems Are Directly Linked through the Activation of Interleukin-1α by Thrombin. Immunity. 2019, 50, 1033–1042. [Google Scholar] [CrossRef]
- Fang X, Liao R, Yu Y, Li J, Guo Z, Zhu T. Thrombin Induces Secretion of Multiple Cytokines and Expression of Protease-Activated Receptors in Mouse Mast Cell Line. Mediators Inflamm. 2019, 2019, 4952131. [Google Scholar] [CrossRef]
- Jaberi N, Soleimani A, Pashirzad M, Abdeahad H, Mohammadi F, Khoshakhlagh M, Khazaei M, Ferns GA, Avan A, Hassanian SM. Role of thrombin in the pathogenesis of atherosclerosis. J Cell Biochem. 2019, 120, 4757–4765. [Google Scholar] [CrossRef]
- Bea F, Kreuzer J, Preusch M, Schaab S, Isermann B, Rosenfeld ME, Katus H, Blessing E. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006, 26, 2787–2792. [Google Scholar] [CrossRef] [PubMed]
- Grebe A, Hoss F, Latz E. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. Circ Res. 2018, 122, 1722–1740. [Google Scholar] [CrossRef] [PubMed]
- Latz E, Xiao TS, Stutz A. Activation and Regulation of the Inflammasomes. Nat Rev Immunol. 2013, 13, 397–411. [CrossRef]
- Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996, 16, 1000–1006. [Google Scholar] [CrossRef]
- Joosten LA, Netea MG, Fantuzzi G, Koenders MI, Helsen MM, Sparrer H, Pham CT, van der Meer JW, Dinarello CA, van den Berg WB. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin- 1beta. Arthritis Rheum. 2009, 60, 3651–3662. [CrossRef]
- Weber A, Wasiliew P, Kracht M. Interleukin-1beta (IL-1beta) processing pathway. Sci Signal. 2010, 3, cm2. [Google Scholar] [CrossRef]
- Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 3. [CrossRef]
- Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest. 1990, 85, 731–738. [CrossRef]
- Dinarello, CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009, 27, 519–550. [Google Scholar] [CrossRef]
- Beltrami-Moreira M, Vromman A, Sukhova GK, Folco EJ, Libby P. Redundancy of IL-1 Isoform Signaling and Its Implications for Arterial Remodeling. PLoS One. 2016, 11, e0152474. [Google Scholar] [CrossRef]
- Libby, P. Collagenases and cracks in the plaque. J Clin Invest. 2013, 123, 3201–3203. [Google Scholar] [CrossRef]
- Libby, P. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Am Coll Cardiol. 2017, 70, 2278–2289. [Google Scholar] [CrossRef]
- Vromman A, Ruvkun V, Shvartz E, Wojtkiewicz G, Santos Masson G, Tesmenitsky Y, Folco E, Gram H, Nahrendorf M, Swirski FK, Sukhova GK, Libby P. Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis. Eur Heart J. 2019, 40, 2482–2491. [Google Scholar] [CrossRef] [PubMed]
- Kamari Y, Shaish A, Shemesh S, Vax E, Grosskopf I, Dotan S, White M, Voronov E, Dinarello CA, Apte RN, Harats D. Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1α. Biochem Biophys Res Commun. 2011, 405, 197–203. [CrossRef]
- Libby P, Warner SJ, Friedman GB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest. 1988, 81, 487–498. [Google Scholar] [CrossRef] [PubMed]
- Tsioufis P, Theofilis P, Tsioufis K, Tousoulis D. The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches. Int J Mol Sci. 2022, 23, 15937. [Google Scholar] [CrossRef]
- Dinarello, CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018, 281, 8–27. [Google Scholar] [CrossRef]
- Herder C, de Las Heras Gala T, Carstensen-Kirberg M, Huth C, Zierer A, Wahl S, Sudduth-Klinger J, Kuulasmaa K, Peretz D, Ligthart S, Bongaerts BWC, Dehghan A, Ikram MA, Jula A, Kee F, Pietilä A, Saarela O, Zeller T, Blankenberg S, Meisinger C, Peters A, Roden M, Salomaa V, Koenig W, Thorand B. Circulating Levels of Interleukin 1-Receptor Antagonist and Risk of Cardiovascular Disease: Meta-Analysis of Six Population-Based Cohorts. Arterioscler Thromb Vasc Biol. 2017, 37, 1222–1227. [Google Scholar] [CrossRef]
- Mai W, Liao Y. Targeting IL-1β in the Treatment of Atherosclerosis. Front Immunol. 2020, 11, 589654. [Google Scholar] [CrossRef]
- Lee YW, Hirani AA. Role of interleukin-4 in atherosclerosis. Arch Pharm Res. 2006, 29, 1–15. [Google Scholar] [CrossRef]
- Galéa P, Thibault G, Lacord M, Bardos P, Lebranchu Y. IL-4, but not tumor necrosis factor-alpha, increases endothelial cell adhesiveness for lymphocytes by activating a cAMP-dependent pathway. J Immunol. 1993, 151, 588–596. [Google Scholar] [CrossRef]
- Lee YW, Hennig B, Toborek M. Redox-regulated mechanisms of IL-4-induced MCP-1 expression in human vascular endothelial cells. Am J Physiol Heart Circ Physiol. 2003, 284, H185–H192. [Google Scholar] [CrossRef] [PubMed]
- Iademarco MF, Barks JL, Dean DC. Regulation of vascular cell adhesion molecule-1 expression by IL-4 and TNF-alpha in cultured endothelial cells. J Clin Invest. 1995, 95, 264–271. [Google Scholar] [CrossRef] [PubMed]
- Ali M, Girgis S, Hassan A, Rudick S, Becker RC. Inflammation and coronary artery disease: from pathophysiology to Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Coron Artery Dis. 2018, 29, 429–437. [Google Scholar] [CrossRef]
- Silveira A, McLeod O, Strawbridge RJ, Gertow K, Sennblad B, Baldassarre D, Veglia F, Deleskog A, Persson J, Leander K, Gigante B, Kauhanen J, Rauramaa R, Smit AJ, Mannarino E, Giral P, Gustafsson S, Söderberg S, Öhrvik J, Humphries SE, Tremoli E, de Faire U, Hamsten A. Plasma IL-5 concentration and subclinical carotid atherosclerosis. Atherosclerosis. 2015, 239, 125–130. [Google Scholar] [CrossRef] [PubMed]
- Ishigami T, Abe K, Aoki I, Minegishi S, Ryo A, Matsunaga S, Matsuoka K, Takeda H, Sawasaki T, Umemura S, Endo Y. Anti-interleukin-5 and multiple autoantibodies are associated with human atherosclerotic diseases and serum interleukin-5 levels. FASEB J. 2013, 27, 3437–3445. [Google Scholar] [CrossRef]
- Zhao W, Lei T, Li H, Sun D, Mo X, Wang Z, Zhang K, Ou H. Macrophage-specific overexpression of interleukin-5 attenuates atherosclerosis in LDL receptor-deficient mice. Gene Ther. 2015, 22, 645–652. [Google Scholar] [CrossRef]
- Ren W, Wang Z, Wang J, Wu Z, Ren Q, Yu A, Ruan Y. IL-5 overexpression attenuates aortic dissection by reducing inflammation and smooth muscle cell apoptosis. Life Sci. 2020, 241, 117144. [Google Scholar] [CrossRef]
- Kazemi Fard T, Ahmadi R, Akbari T, Moradi N, Fadaei R, Kazemi Fard M, Fallah S. Klotho, FOXO1 and cytokines associations in patients with coronary artery disease. Cytokine. 2021, 141, 155443. [Google Scholar] [CrossRef]
- Schrader JW, Moyer C, Ziltener HJ, Reinisch CL. Release of the cytokines colony-stimulating factor-1, granulocyte-macrophage colony-stimulating factor, and IL-6 by cloned murine vascular smooth muscle cells. J Immunol. 1991, 146, 3799–3808. [Google Scholar] [CrossRef]
- Reiss AB, Siegart NM; De Leon, J. Interleukin-6 in atherosclerosis: Atherogenic or atheroprotective? Clin. Lipidol. 2017, 12, 14–23. [Google Scholar]
- Schaper F, Rose-John S. Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 2015, 26, 475–487. [Google Scholar] [CrossRef] [PubMed]
- Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998, 101, 311–320. [Google Scholar] [CrossRef] [PubMed]
- Rose-John, S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012, 8, 1237–1247. [Google Scholar] [CrossRef] [PubMed]
- Arya AK, Tripathi R, Kumar S, Tripathi K. Recent advances on the association of apoptosis in chronic non healing diabetic wound. World J Diabetes. 2014, 5, 756–762. [Google Scholar] [CrossRef]
- Li R, Paul A, Ko KW, Sheldon M, Rich BE, Terashima T, Dieker C, Cormier S, Li L, Nour EA, Chan L, Oka K. Interleukin-7 induces recruitment of monocytes/macrophages to endothelium. Eur Heart J. 2012, 33, 3114–3123. [Google Scholar] [CrossRef]
- Morishita R, Makino H, Aoki M, Hashiya N, Yamasaki K, Azuma J, Taniyama Y, Sawa Y, Kaneda Y, Ogihara T. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol. 2011, 31, 713–720. [Google Scholar] [CrossRef]
- Zhang W, Tang T, Nie D, Wen S, Jia C, Zhu Z, Xia N, Nie S, Zhou S, Jiao J, Dong W, Lv B, Xu T, Sun B, Lu Y, Li Y, Cheng L, Liao Y, Cheng X. IL-9 aggravates the development of atherosclerosis in ApoE-/- mice. Cardiovasc Res. 2015, 106, 453–464. [Google Scholar] [CrossRef]
- Von Der Thüsen JH, Kuiper J, Fekkes ML, De Vos P, Van Berkel TJ, Biessen EA. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J. 2001, 15, 2730–2732. [Google Scholar] [CrossRef]
- Mittal SK, Cho KJ, Ishido S, Roche PA. Interleukin 10 (IL-10)-mediated Immunosuppression: March-I induction regulates antigen presentation by macrophages but not dendritic cells. J Biol Chem. 2015, 290, 27158–27167. [Google Scholar] [CrossRef]
- Han X, Boisvert WA. Interleukin-10 protects against atherosclerosis by modulating multiple atherogenic macrophage function. Thromb Haemost. 2015, 113, 505–512. [Google Scholar] [CrossRef]
- Tan H, Dan G, Gong H, Cao L. Purification and characterization of recombinant truncated human interleukin-11 expressed as fusion protein in Escherichia coli. Biotechnol Lett. 2005, 27, 905–910. [Google Scholar] [CrossRef] [PubMed]
- Vascular effects of glycoprotein130 ligands--part I: pathophysiologicalrole. Vascul Pharmacol. 2012; 56(1-2): 34-46. [CrossRef]
- Abu El-Asrar AM, Ahmad A, Allegaert E, Siddiquei MM, Gikandi PW, De Hertogh G, Opdenakker G. Interleukin-11 Overexpression and M2 Macrophage Density are Associated with Angiogenic Activity in Proliferative Diabetic Retinopathy. Ocul Immunol Inflamm. 2020, 28, 575–588. [Google Scholar] [CrossRef] [PubMed]
- Roger I, Estornut C, Ballester B, Milara J, Cortijo J. Role of IL‐11 in vascular function of pulmonary fibrosis patients. Eur Respir J. 2019; 54(suppl 63): PA1424. [CrossRef]
- Elshabrawy HA, Volin MV, Essani AB, Chen Z, McInnes IB, Van Raemdonck K, Palasiewicz K, Arami S, Gonzalez M, Ashour HM, Kim SJ, Zhou G, Fox DA, Shahrara S. IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cells. Angiogenesis. 2018, 21, 215–228. [Google Scholar] [CrossRef] [PubMed]
- Lamertz L, Rummel F, Polz R, Baran P, Hansen S, Waetzig GH, Moll JM, Floss DM, Scheller J. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses. Sci Signal. 2018, 11, eaar7388. [CrossRef]
- Guo YT, Lu YY, Lu X, He S, Li SJ, Shao S, Zhou HD, Wang RQ, Li XD, Gao PJ. Krüppel-Like Factor 15/Interleukin 11 Axis-Mediated Adventitial Remodeling Depends on Extracellular Signal-Regulated Kinases 1 and 2 Activation in Angiotensin II-Induced Hypertension. J Am Heart Assoc. 2021, 10, e020554. [Google Scholar] [CrossRef]
- Mahboubi K, Biedermann BC, Carroll JM, Pober JS. IL-11 activates human endothelial cells to resist immune-mediated injury. J Immunol. 2000, 164, 3837–3846. [Google Scholar] [CrossRef]
- Lim WW, Corden B, Ng B, Vanezis K, D’Agostino G, Widjaja AA, Song WH, Xie C, Su L, Kwek XY, Tee NGZ, Dong J, Ko NSJ, Wang M, Pua CJ, Jamal MH, Soh B, Viswanathan S, Schafer S, Cook SA. Interleukin-11 is important for vascular smooth muscle phenotypic switching and aortic inflammation, fibrosis and remodeling in mouse models. Sci Rep. 2020, 10, 17853. [Google Scholar] [CrossRef]
- Widjaja AA, Viswanathan S, Jinrui D, Singh BK, Tan J, Wei Ting JG, Lamb D, Shekeran SG, George BL, Schafer S, Carling D, Adami E, Cook SA. Molecular Dissection of Pro-Fibrotic IL11 Signaling in Cardiac and Pulmonary Fibroblasts. Front Mol Biosci. 2021, 8, 740650. [Google Scholar] [CrossRef]
- Ye J, Wang Y, Wang Z, Liu L, Yang Z, Wang M, Xu Y, Ye D, Zhang J, Lin Y, Ji Q, Wan J. Roles and Mechanisms of Interleukin-12 Family Members in Cardiovascular Diseases: Opportunities and Challenges. Front Pharmacol. 2020, 11, 129. [Google Scholar] [CrossRef]
- Andrews C, McLean MH, Durum SK. Interleukin-27 as a Novel Therapy for Inflammatory Bowel Disease: A Critical Review of the Literature. Inflamm Bowel Dis. 2016, 22, 2255–2264. [Google Scholar] [CrossRef]
- Kan X, Wu Y, Ma Y, Zhang C, Li P, Wu L, Zhang S, Li Y, Du J. Deficiency of IL-12p35 improves cardiac repair after myocardial infarction by promoting angiogenesis. Cardiovasc Res. 2016, 109, 249–259. [Google Scholar] [CrossRef] [PubMed]
- Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006, 12, 99–106. [Google Scholar] [CrossRef] [PubMed]
- Fatkhullina AR, Peshkova IO, Koltsova EK. The Role of Cytokines in the Development of Atherosclerosis. Biochemistry (Mosc). 2016, 81, 1358–1370. [Google Scholar] [CrossRef] [PubMed]
- Cardilo-Reis L, Gruber S, Schreier SM, Drechsler M, Papac-Milicevic N, Weber C, Wagner O, Stangl H, Soehnlein O, Binder CJ. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol Med. 2012, 4, 1072–1086. [Google Scholar] [CrossRef]
- Rossol M, Heine H, Meusch U, Quandt D, Klein C, Sweet MJ, Hauschildt S. LPS-induced cytokine production in human monocytes and macrophages. Crit Rev Immunol. 2011, 31, 379–446. [Google Scholar] [CrossRef]
- Guo L, Liu MF, Huang JN, Li JM, Jiang J, Wang JA. Role of interleukin-15 in cardiovascular diseases. J Cell Mol Med. 2020, 24, 7094–7101. [Google Scholar] [CrossRef]
- Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature. 2008, 453, 1051–1057. [Google Scholar] [CrossRef]
- Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J, Lebecque S. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996, 183, 2593–2603. [Google Scholar] [CrossRef]
- McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 Family of Cytokines in Health and Disease. Immunity. 2019, 50, 892–906. [Google Scholar] [CrossRef]
- Faour WH, Mancini A, He QW, Di Battista JA. T-cell-derived interleukin-17 regulates the level and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of the p38 mitogen-activated protein kinase cascade: role of distal sequences in the 3’-untranslated region of COX-2 mRNA. J Biol Chem. 2003, 278, 26897–26907. [Google Scholar] [CrossRef]
- Kidani Y, Bensinger SJ. Reviewing the impact of lipid synthetic flux on Th17 function. Curr Opin Immunol. 2017, 46, 121–126. [Google Scholar] [CrossRef] [PubMed]
- Taleb S, Tedgui A, Mallat Z. Interleukin-17: friend or foe in atherosclerosis? Curr Opin Lipidol. 2010, 21, 404–408. [CrossRef]
- O’Connor W Jr, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, Kolls JK, Flavell RA. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009, 10, 603–609. [Google Scholar] [CrossRef] [PubMed]
- Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O, Esposito B, Perez N, Yasukawa H, Van Snick J, Yoshimura A, Tedgui A, Mallat Z. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med. 2009, 206, 2067–2077. [Google Scholar] [CrossRef]
- Danzaki K, Matsui Y, Ikesue M, Ohta D, Ito K, Kanayama M, Kurotaki D, Morimoto J, Iwakura Y, Yagita H, Tsutsui H, Uede T. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2012, 32, 273–280. [Google Scholar] [CrossRef]
- Erbel C, Dengler TJ, Wangler S, Lasitschka F, Bea F, Wambsganss N, Hakimi M, Böckler D, Katus HA, Gleissner CA. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol. 2011, 106, 125–134. [Google Scholar] [CrossRef]
- Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, Gallo A, Sokol SI, Pfau S, Pober JS, Tellides G. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation. 2009, 119, 1424–1432. [Google Scholar] [CrossRef]
- Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schönbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002, 195, 245–257. [Google Scholar] [CrossRef]
- Netea MG, Kullberg BJ, Verschueren I, Van Der Meer JW. Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta. Eur J Immunol. 2000, 30, 3057–3060. [CrossRef]
- Kannan Y, Yu J, Raices RM, Seshadri S, Wei M, Caligiuri MA, Wewers MD. IκBζ augments IL-12- and IL-18-mediated IFN-γ production in human NK cells. Blood. 2011, 117, 2855–2863. [Google Scholar] [CrossRef]
- Gallagher, G. Interleukin-19: multiple roles in immune regulation and disease. Cytokine Growth Factor Rev. 2010, 21, 345–352. [Google Scholar] [CrossRef] [PubMed]
- Gabunia K, Ellison S, Kelemen S, Kako F, Cornwell WD, Rogers TJ, Datta PK, Ouimet M, Moore KJ, Autieri MV. IL-19 Halts Progression of Atherosclerotic Plaque, Polarizes, and Increases Cholesterol Uptake and Efflux in Macrophages. Am J Pathol. 2016, 186, 1361–1374. [Google Scholar] [CrossRef] [PubMed]
- Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A, Caligiuri G. Macrophage plasticity in experimental atherosclerosis. PLoS One. 2010, 5, e8852. [Google Scholar] [CrossRef]
- Williams KJ, Feig JE, Fisher EA. Cellular and molecular mechanisms for rapid regression of atherosclerosis: from bench top to potentially achievable clinical goal. Curr Opin Lipidol. 2007, 18, 443–450. [Google Scholar] [CrossRef] [PubMed]
- Francis AA, Pierce GN. An integrated approach for the mechanisms responsible for atherosclerotic plaque regression. Exp Clin Cardiol. 2011, 16, 77–86. [Google Scholar]
- Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol. 2006, 26, 1702–1711. [Google Scholar] [CrossRef]
- Rubic T, Lorenz RL. Downregulated CD36 and oxLDL uptake and stimulated ABCA1/G1 and cholesterol efflux as anti-atherosclerotic mechanisms of interleukin-10. Cardiovasc Res. 2006, 69, 527–535. [CrossRef]
- Moore KJ, Kunjathoor VV, Koehn SL, Manning JJ, Tseng AA, Silver JM, McKee M, Freeman MW. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest. 2005, 115, 2192–2201. [Google Scholar] [CrossRef]
- Kozarsky KF, Donahee MH, Glick JM, Krieger M, Rader DJ. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol. 2000, 20, 721–727. [Google Scholar] [CrossRef]
- Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23, 549–555. [Google Scholar] [CrossRef]
- Ellison S, Gabunia K, Kelemen SE, England RN, Scalia R, Richards JM, Orr AW, Traylor JG Jr, Rogers T, Cornwell W, Berglund LM, Goncalves I, Gomez MF, Autieri MV. Attenuation of experimental atherosclerosis by interleukin-19. Arterioscler Thromb Vasc Biol. 2013, 33, 2316–2324. [CrossRef]
- Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD, Sterry W, Asadullah K, Sabat R. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol. 2006, 15, 991–1004. [Google Scholar] [CrossRef] [PubMed]
- Oral HB, Kotenko SV, Yilmaz M, Mani O, Zumkehr J, Blaser K, Akdis CA, Akdis M. Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26. Eur J Immunol. 2006, 36, 380–388. [CrossRef]
- Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol. 2008, 121, 1108–1111. [CrossRef]
- Chen WY, Cheng BC, Jiang MJ, Hsieh MY, Chang MS. IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006, 26, 2090–2095. [Google Scholar] [CrossRef]
- Hsieh MY, Chen WY, Jiang MJ, Cheng BC, Huang TY, Chang MS. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun. 2006, 7, 234–242. [Google Scholar] [CrossRef]
- Xia Q, Xiang X, Patel S, Puranik R, Xie Q, Bao S. Characterisation of IL-22 and interferon-gamma-inducible chemokines in human carotid plaque. Int J Cardiol. 2012, 154, 187–189. [Google Scholar] [CrossRef]
- Rattik S, Hultman K, Rauch U, Söderberg I, Sundius L, Ljungcrantz I, Hultgårdh-Nilsson A, Wigren M, Björkbacka H, Fredrikson GN, Nilsson J. IL-22 affects smooth muscle cell phenotype and plaque formation in apolipoprotein E knockout mice. Atherosclerosis. 2015, 242, 506–514. [Google Scholar] [CrossRef]
- Chellan B, Yan L, Sontag TJ, Reardon CA, Hofmann Bowman MA. IL-22 is induced by S100/calgranulin and impairs cholesterol efflux in macrophages by downregulating ABCG1. J Lipid Res. 2014, 55, 443–454. [CrossRef]
- Che Y, Su Z, Xia L. Effects of IL-22 on cardiovascular diseases. Int Immunopharmacol. 2020, 81, 106277. [Google Scholar] [CrossRef]
- Luo JW, Hu Y, Liu J, Yang H, Huang P. Interleukin-22: a potential therapeutic target in atherosclerosis. Mol Med. 2021, 27, 88. [Google Scholar] [CrossRef] [PubMed]
- Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009, 27, 485–517. [Google Scholar] [CrossRef] [PubMed]
- Wang J, Zhao P, Gao Y, Zhang F, Yuan X, Jiao Y, Gong K. The Effects of Anti-IL-23p19 Therapy on Atherosclerosis Development in ApoE-/- Mice. J Interferon Cytokine Res. 2019, 39, 564–571. [Google Scholar] [CrossRef] [PubMed]
- Abbas A, Gregersen I, Holm S, Daissormont I, Bjerkeli V, Krohg-Sørensen K, Skagen KR, Dahl TB, Russell D, Almås T, Bundgaard D, Alteheld LH, Rashidi A, Dahl CP, Michelsen AE, Biessen EA, Aukrust P, Halvorsen B, Skjelland M. Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis. Stroke. 2015, 46, 793–799. [Google Scholar] [CrossRef]
- Subramanian M, Thorp E, Tabas I. Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling. Circ Res. 2015, 116, e13–e24. [Google Scholar] [CrossRef]
- Fatkhullina AR, Peshkova IO, Dzutsev A, Aghayev T, McCulloch JA, Thovarai V, Badger JH, Vats R, Sundd P, Tang HY, Kossenkov AV, Hazen SL, Trinchieri G, Grivennikov SI, Koltsova EK. An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity. 2018, 49, 943–957. [Google Scholar] [CrossRef]
- Engelbertsen D, Depuydt MAC, Verwilligen RAF, Rattik S, Levinsohn E, Edsfeldt A, Kuperwaser F, Jarolim P, Lichtman AH. IL-23R Deficiency Does Not Impact Atherosclerotic Plaque Development in Mice. J Am Heart Assoc. 2018, 7, e008257. [Google Scholar] [CrossRef]
- Vargas-Alarcón G, Posadas-Romero C, Villarreal-Molina T, Alvarez-León E, Angeles-Martinez J, Posadas-Sanchez R, Monroy-Muñoz I, Luna-Fuentes S, González-Salazar C, Ramirez-Bello J, Cardoso-Saldaña G, Medina-Urrutia A, Kimura-Hayama E. IL-24 gene polymorphisms are associated with cardiometabolic parameters and cardiovascular risk factors but not with premature coronary artery disease: the genetics of atherosclerotic disease Mexican study. J Interferon Cytokine Res. 2014, 34, 659–666. [Google Scholar] [CrossRef]
- Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, Menon S, Clifford T, Hunte B, Lesley R, Muchamuel T, Hurst SD, Zurawski G, Leach MW, Gorman DM, Rennick DM. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001, 15, 985–995. [Google Scholar] [CrossRef]
- Mantani PT, Dunér P, Bengtsson E, Ljungcrantz I, Sundius L, To F, Nilsson J, Björkbacka H, Fredrikson GN. Interleukin-25 (IL-25) has a protective role in atherosclerosis development in the aortic arch in mice. J Biol Chem. 2018, 293, 6791–6801. [Google Scholar] [CrossRef]
- Daugherty, A. Mouse models of atherosclerosis. Am J Med Sci. 2002, 323, 3–10. [Google Scholar] [CrossRef] [PubMed]
- Mantani PT, Dunér P, Bengtsson E, Alm R, Ljungcrantz I, Söderberg I, Sundius L, To F, Nilsson J, Björkbacka H, Fredrikson GN. IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice. PLoS One. 2015, 10, e0117255. [Google Scholar] [CrossRef]
- Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annu Rev Immunol. 2015, 33, 417–43. [CrossRef]
- Koltsova EK, Kim G, Lloyd KM, Saris CJ, von Vietinghoff S, Kronenberg M, Ley K. Interleukin-27 receptor limits atherosclerosis in Ldlr-/- mice. Circ Res. 2012, 111, 1274–1285. [Google Scholar] [CrossRef]
- Hirase T, Hara H, Miyazaki Y, Ide N, Nishimoto-Hazuku A, Fujimoto H, Saris CJ, Yoshida H, Node K. Interleukin 27 inhibits atherosclerosis via immunoregulation of macrophages in mice. Am J Physiol Heart Circ Physiol. 2013, 305, H420–H429. [Google Scholar] [CrossRef]
- Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y, Yamamoto K. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther. 2006, 8, R166. [Google Scholar] [CrossRef]
- Park MH, Song MJ, Cho MC, Moon DC, Yoon DY, Han SB, Hong JT. Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Immunology. 2012, 135, 63–72. [CrossRef]
- Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, Guo X, Kang B, Hu R, Huang JY, Zhang Q, Liu Z, Dong M, Hu X, Ouyang W, Peng J, Zhang Z. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell. 2017, 169, 1342–1356. [Google Scholar] [CrossRef]
- Nold-Petry CA, Nold MF, Zepp JA, Kim SH, Voelkel NF, Dinarello CA. IL-32-dependent effects of IL-1beta on endothelial cell functions. Proc Natl Acad Sci U S A. 2009, 106, 3883–3888. [Google Scholar] [CrossRef]
- Kobayashi H, Lin PC. Molecular characterization of IL-32 in human endothelial cells. Cytokine. 2009, 46, 351–358. [Google Scholar] [CrossRef]
- Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH. Interleukin 32, inflammation and cancer. Pharmacol Ther. 2017, 174, 127–137. [Google Scholar] [CrossRef] [PubMed]
- Zaidan SM, Leyre L, Bunet R, Larouche-Anctil E, Turcotte I, Sylla M, Chamberland A, Chartrand-Lefebvre C, Ancuta P, Routy JP, Baril JG, Trottier B, MacPherson P, Trottier S, Harris M, Walmsley S, Conway B, Wong A, Thomas R, Kaplan RC, Landay AL, Durand M, Chomont N, Tremblay CL, El-Far M; Canadian HIV and Aging Cohort Study. Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs. J Acquir Immune Defic Syndr. 2019, 82, 503–513. [Google Scholar] [CrossRef] [PubMed]
- Mohammad-Rezaei M, Ahmadi R, Rafiei A, Khaledifar A, Fattahi S, Samiei-Sefat A, Emami S, Bagheri N. Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF-α. Mol Biol Rep. 2021, 48, 4263–4271. [CrossRef]
- Yang Z, Shi L, Xue Y, Zeng T, Shi Y, Lin Y, Liu L. Interleukin-32 increases in coronary arteries and plasma from patients with coronary artery disease. Clin Chim Acta. 2019, 497, 104–109. [Google Scholar] [CrossRef] [PubMed]
- Heinhuis B, Popa CD, van Tits BL, Kim SH, Zeeuwen PL, van den Berg WB, van der Meer JW, van der Vliet JA, Stalenhoef AF, Dinarello CA, Netea MG, Joosten LA. Towards a role of interleukin-32 in atherosclerosis. Cytokine. 2013, 64, 433–440. [Google Scholar] [CrossRef]
- Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005, 22, 131–142. [Google Scholar] [CrossRef]
- Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E, Kim JM, Yoon DY, Dinarello CA, Kim SH. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A. 2005, 102, 16309–16314. [Google Scholar] [CrossRef]
- Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H, Kim J, Kim YM, Kwon YG. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood. 2009, 114, 3117–3126. [Google Scholar] [CrossRef]
- Lu J, Kang J, Zhang C, Zhang X. The role of IL-33/ST2L signals in the immune cells. Immunol Lett. 2015, 164, 11–7. [Google Scholar] [CrossRef]
- McLaren JE, Michael DR, Salter RC, Ashlin TG, Calder CJ, Miller AM, Liew FY, Ramji DP. IL-33 reduces macrophage foam cell formation. J Immunol. 2010, 185, 1222–1229. [Google Scholar] [CrossRef]
- Zhang HF, Wu MX, Lin YQ, Xie SL, Huang TC, Liu PM, Nie RQ, Meng QQ, Luo NS, Chen YX, Wang JF. IL-33 promotes IL-10 production in macrophages: a role for IL-33 in macrophage foam cell formation. Exp Mol Med. 2017, 49, e388. [Google Scholar] [CrossRef] [PubMed]
- Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB, Liew FY. IL-33 reduces the development of atherosclerosis. J Exp Med. 2008, 205, 339–346. [Google Scholar] [CrossRef] [PubMed]
- Wei X, Zhang J, Gu Q, Huang M, Zhang W, Guo J, Zhou X. Reciprocal Expression of IL-35 and IL-10 Defines Two Distinct Effector Treg Subsets that Are Required for Maintenance of Immune Tolerance. Cell Rep. 2017, 21, 1853–1869. [Google Scholar] [CrossRef] [PubMed]
- Sha X, Meng S, Li X, Xi H, Maddaloni M, Pascual DW, Shan H, Jiang X, Wang H, Yang XF. Interleukin-35 Inhibits Endothelial Cell Activation by Suppressing MAPK-AP-1 Pathway. J Biol Chem. 2015, 290, 19307–19318. [Google Scholar] [CrossRef]
- Jia D, Jiang H, Weng X, Wu J, Bai P, Yang W, Wang Z, Hu K, Sun A, Ge J. Interleukin-35 Promotes Macrophage Survival and Improves Wound Healing After Myocardial Infarction in Mice. Circ Res. 2019, 124, 1323–1336. [Google Scholar] [CrossRef]
- Liu J, Lin J, He S, Wu C, Wang B, Liu J, Duan Y, Liu T, Shan S, Yang K, Dong N, Ji Q, Huang K, Li D. Transgenic Overexpression of IL-37 Protects Against Atherosclerosis and Strengthens Plaque Stability. Cell Physiol Biochem. 2018, 45, 1034–1050. [Google Scholar] [CrossRef]
- Sharma S, Kulk N, Nold MF, Gräf R, Kim SH, Reinhardt D, Dinarello CA, Bufler P. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol. 2008, 180, 5477–5482. [Google Scholar] [CrossRef]
- Bulau AM, Nold MF, Li S, Nold-Petry CA, Fink M, Mansell A, Schwerd T, Hong J, Rubartelli A, Dinarello CA, Bufler P. Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. Proc Natl Acad Sci U S A. 2014, 111, 2650–2655. [Google Scholar] [CrossRef]
- Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010, 11, 1014–1022. [Google Scholar] [CrossRef]
- Chai M, Ji Q, Zhang H, Zhou Y, Yang Q, Zhou Y, Guo G, Liu W, Han W, Yang L, Zhang L, Liang J, Liu Y, Shi D, Zhao Y. The Protective Effect of Interleukin-37 on Vascular Calcification and Atherosclerosis in Apolipoprotein E-Deficient Mice with Diabetes. J Interferon Cytokine Res. 2015, 35, 530–539. [Google Scholar] [CrossRef]
- Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol. 2009, 9, 447–453. [Google Scholar] [CrossRef] [PubMed]
- Flusberg DA, Sorger PK. Surviving apoptosis: life-death signaling in single cells. Trends Cell Biol. 2015, 25, 446–458. [Google Scholar] [CrossRef] [PubMed]
- Nash M, McGrath JP, Cartland SP, Patel S, Kavurma MM. Tumour necrosis factor superfamily members in ischaemic vascular diseases. Cardiovasc Res. 2019, 115, 713–720. [Google Scholar] [CrossRef] [PubMed]
- Mackesy DZ, Goalstone ML. Extracellular signal-regulated kinase-5: Novel mediator of insulin and tumor necrosis factor α-stimulated vascular cell adhesion molecule-1 expression in vascular cells. J Diabetes. 2014, 6, 595–602. [Google Scholar] [CrossRef]
- Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol. 1992, 140, 301–316. [Google Scholar]
- Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006, 86, 515–581. [Google Scholar] [CrossRef]
- Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, Saito K, Sekikawa K, Seishima M. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis. 2005, 180, 11–17. [Google Scholar] [CrossRef]
- Hashizume M, Mihara M. Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors. Cytokine. 2012, 58, 424–430. [Google Scholar] [CrossRef]
- Levy Z, Rachmani R, Trestman S, Dvir A, Shaish A, Ravid M, Harats D. Low-dose interferon-alpha accelerates atherosclerosis in an LDL receptor-deficient mouse model. Eur J Intern Med. 2003, 14, 479–483. [Google Scholar] [CrossRef]
- Pepper MS, Mandriota SJ, Vassalli JD, Orci L, Montesano R. Angiogenesis-regulating cytokines: activities and interactions. Curr Top Microbiol Immunol. 3: 2). [CrossRef]
- Pammer J, Reinisch C, Birner P, Pogoda K, Sturzl M, Tschachler E. Interferon-alpha prevents apoptosis of endothelial cells after short-term exposure but induces replicative senescence after continuous stimulation. Lab Invest. 2006, 86, 997–1007. [Google Scholar] [CrossRef]
- Ruszczak Z, Detmar M, Imcke E, Orfanos CE. Effects of rIFN alpha, beta, and gamma on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells in vitro. J Invest Dermatol. 1990, 95, 693–699. [Google Scholar] [CrossRef] [PubMed]
- Minischetti M, Vacca A, Ribatti D, Iurlaro M, Ria R, Pellegrino A, Gasparini G, Dammacco AF. TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically. Br J Haematol. 2000, 109, 829–837. [CrossRef]
- Cozzolino F, Torcia M, Lucibello M, Morbidelli L, Ziche M, Platt J, Fabiani S, Brett J, Stern D. Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J Clin Invest. 1993, 91, 2504–2512. [Google Scholar] [CrossRef] [PubMed]
- Gomez D, Reich NC. Stimulation of primary human endothelial cell proliferation by IFN. J Immunol. 2003, 170, 5373–5381. [Google Scholar] [CrossRef] [PubMed]
- Sgonc R, Fuerhapter C, Boeck G, Swerlick R, Fritsch P, Sepp N. Induction of apoptosis in human dermal microvascular endothelial cells and infantile hemangiomas by interferon-alpha. Int Arch Allergy Immunol. 1998, 117, 209–214. [Google Scholar]
- Boshuizen MC, de Winther MP. Interferons as Essential Modulators of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2015, 35, 1579–1588. [Google Scholar] [CrossRef]
- Butticè G, Miller J, Wang L, Smith BD. Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells. Circ Res. 2006, 98, 472–479. [Google Scholar] [CrossRef]
- Ahmad U, Ali R, Lebastchi AH, Qin L, Lo SF, Yakimov AO, Khan SF, Choy JC, Geirsson A, Pober JS, Tellides G. IFN-gamma primes intact human coronary arteries and cultured coronary smooth muscle cells to double-stranded RNA- and self-RNA-induced inflammatory responses by upregulating TLR3 and melanoma differentiation-associated gene 5. J Immunol. 2010, 185, 1283–1294. [CrossRef]
- Zhou QD, Chi X, Lee MS, Hsieh WY, Mkrtchyan JJ, Feng AC, He C, York AG, Bui VL, Kronenberger EB, Ferrari A, Xiao X, Daly AE, Tarling EJ, Damoiseaux R, Scumpia PO, Smale ST, Williams KJ, Tontonoz P, Bensinger SJ. Interferon-mediated reprogramming of membrane cholesterol to evade bacterial toxins. Nat Immunol. 2020, 21, 746–755. [Google Scholar] [CrossRef]
- Mehta NN, Teague HL, Swindell WR, Baumer Y, Ward NL, Xing X, Baugous B, Johnston A, Joshi AA, Silverman J, Barnes DH, Wolterink L, Nair RP, Stuart PE, Playford M, Voorhees JJ, Sarkar MK, Elder JT, Gallagher K, Ganesh SK, Gudjonsson JE. IFN-γ and TNF-α synergism may provide a link between psoriasis and inflammatory atherogenesis. Sci Rep. 2017, 7, 13831. [Google Scholar] [CrossRef]
- Gupta S, Pablo AM, Jiang Xc, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997, 99, 2752–2761. [Google Scholar] [CrossRef] [PubMed]
- Serralheiro P, Soares A, Costa Almeida CM, Verde I. TGF-β1 in Vascular Wall Pathology: Unraveling Chronic Venous Insufficiency Pathophysiology. Int J Mol Sci. 2017, 18, 2534. [Google Scholar] [CrossRef]
- Chen PY, Qin L, Tellides G, Simons M. Fibroblast growth factor receptor 1 is a key inhibitor of TGFβ signaling in the endothelium. Sci Signal. 2014, 7, ra90. [Google Scholar] [CrossRef]
- Ligi D, Croce L, Mosti G, Raffetto JD, Mannello F. Chronic Venous Insufficiency: Transforming Growth Factor-β Isoforms and Soluble Endoglin Concentration in Different States of Wound Healing. Int J Mol Sci. 2017, 18, 2206. [Google Scholar] [CrossRef]
- Golovina VI, Seliverstov EI, Efremova OI, Zolotukhin IA. Cytokines in pathogenesis of varicose veins. Flebologiya. 2021, 15, 117–126. [Google Scholar] [CrossRef]
- Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J. 2016, 37, 1723–1732. [Google Scholar] [CrossRef]
- Ramji DP, Davies TS. Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev. 2015, 26, 673–685. [Google Scholar] [CrossRef]
- Adela R, Banerjee SK. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective. J Diabetes Res. 2015, 2015, 490842. [Google Scholar] [CrossRef]
- Wischhusen J, Melero I, Fridman WH. Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020, 11, 951. [Google Scholar] [CrossRef]
- Wang FF, Chen BX, Yu HY, Mi L, Li ZJ, Gao W. Correlation between growth differentiation factor-15 and collagen metabolism indicators in patients with myocardial infarction and heart failure. J Geriatr Cardiol. 2016, 13, 88–93. [Google Scholar] [CrossRef]
- Wang J, Wei L, Yang X, Zhong J. Roles of Growth Differentiation Factor 15 in Atherosclerosis and Coronary Artery Disease. J Am Heart Assoc. 2019, 8, e012826. [Google Scholar] [CrossRef] [PubMed]
- Lin YD, Luo CY, Hu YN, Yeh ML, Hsueh YC, Chang MY, Tsai DC, Wang JN, Tang MJ, Wei EI, Springer ML, Hsieh PC. Instructive nanofiber scaffolds with VEGF create a microenvironment for arteriogenesis and cardiac repair. Sci Transl Med. 2012, 4, 146ra109. [Google Scholar] [CrossRef]
- Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, Alitalo K, Eriksson U. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol. 2001, 3, 512–516. [CrossRef]
- Cao R, Bråkenhielm E, Li X, Pietras K, Widenfalk J, Ostman A, Eriksson U, Cao Y. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J. 2002, 16, 1575–1583. [Google Scholar] [CrossRef] [PubMed]
- Li X, Pontén A, Aase K, Karlsson L, Abramsson A, Uutela M, Bäckström G, Hellström M, Boström H, Li H, Soriano P, Betsholtz C, Heldin CH, Alitalo K, Ostman A, Eriksson U. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol. 2000, 2, 302–309. [Google Scholar] [CrossRef]
- Xue Y, Lim S, Yang Y, Wang Z, Jensen LD, Hedlund EM, Andersson P, Sasahara M, Larsson O, Galter D, Cao R, Hosaka K, Cao Y. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med. 2011, 18, 100–110. [Google Scholar] [CrossRef]
- Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest. 2003, 112, 1142–1151. [Google Scholar] [CrossRef]
- Hellberg C, Ostman A, Heldin CH. PDGF and vessel maturation. Recent Results Cancer Res. 2010, 180, 103–114. [Google Scholar] [CrossRef]
- Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys. 2002, 398, 284–290. [Google Scholar] [CrossRef]
- Heldin CH, Westermark B. Signal transduction by the receptors for platelet-derived growth factor. J Cell Sci. 1: 2). [CrossRef]
- Martino MM, Brkic S, Bovo E, Burger M, Schaefer DJ, Wolff T, Gürke L, Briquez PS, Larsson HM, Gianni-Barrera R, Hubbell JA, Banfi A. Extracellular matrix and growth factor engineering for controlled angiogenesis in regenerative medicine. Front Bioeng Biotechnol. 2015, 3, 45. [Google Scholar] [CrossRef]
- Li H, Fredriksson L, Li X, Eriksson U. PDGF-D is a potent transforming and angiogenic growth factor. Oncogene. 2003, 22, 1501–1510. [Google Scholar] [CrossRef]
- Cao R, Bråkenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med. 2003, 9, 604–613. [CrossRef]
- Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019, 176, 1248–1264. [Google Scholar] [CrossRef] [PubMed]
- Martínez, C.E. , Smith C., Palma Alvarado V.A. The influence of platelet-derived products on angiogenesis and tissue repair: A concise update. Front. Physiol. 2015, 6, 159973. [Google Scholar] [CrossRef] [PubMed]
- Kemp SS, Lin PK, Sun Z, Castaño MA, Yrigoin K, Penn MR, Davis GE. Molecular basis for pericyte-induced capillary tube network assembly and maturation. Front Cell Dev Biol. 2022, 10, 943533. [Google Scholar] [CrossRef]
- Stratman AN, Davis GE. Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization. Microsc Microanal. 2012, 18, 68–80. [Google Scholar] [CrossRef]
- Holmes D, Fitzgerald P, Goldberg S, LaBlanche Jm, Lincoff AM, Savage M, Serruys PW, Willerson J, Granett JR, Chan R, Shusterman NH, Poland M. The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trial. Am Heart J. 2: Pt1); (1. [CrossRef]
- Stratman AN, Schwindt AE, Malotte KM, Davis GE. Endothelial-derived PDGF-BB and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization. Blood. 2010, 116, 4720–4730. [Google Scholar] [CrossRef]
- Goumans MJ, Ten Dijke P. TGF-β Signaling in Control of Cardiovascular Function. Cold Spring Harb Perspect Biol. 2018, 10, a022210. [Google Scholar] [CrossRef]
- Moriya J, Wu X, Zavala-Solorio J, Ross J, Liang XH, Ferrara N. Platelet-derived growth factor C promotes revascularization in ischemic limbs of diabetic mice. J Vasc Surg. 2014, 59, e1–e4. [Google Scholar] [CrossRef]
- Shah P, Keppler L, Rutkowski J. A review of platelet derived growth factor playing pivotal role in bone regeneration. J Oral Implantol. 2014, 40, 330–340. [Google Scholar] [CrossRef]
- Raza SL, Cornelius LA. Matrix metalloproteinases: pro- and anti-angiogenic activities. J Investig Dermatol Symp Proc. 2000, 5, 47–54. [Google Scholar] [CrossRef] [PubMed]
- Rundhaug, JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005, 9, 267–285. [Google Scholar] [CrossRef] [PubMed]
- Chantrain CF, Henriet P, Jodele S, Emonard H, Feron O, Courtoy PJ, DeClerck YA, Marbaix E. Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur J Cancer. 2006, 42, 310–318. [Google Scholar] [CrossRef] [PubMed]
- Saunders WB, Bohnsack BL, Faske JB, Anthis NJ, Bayless KJ, Hirschi KK, Davis GE. Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J Cell Biol. 2006, 175, 179–191. [CrossRef]
- Dean EW, Udelsman B, Breuer CK. Current advances in the translation of vascular tissue engineering to the treatment of pediatric congenital heart disease. Yale J Biol Med. 2012, 85, 229–238. [Google Scholar]
- Wanjare M, Kusuma S, Gerecht S. Defining differences among perivascular cells derived from human pluripotent stem cells. Stem Cell Reports. 2014, 2, 561–575. [Google Scholar] [CrossRef]
- Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 2003, 314, 15–23. [Google Scholar] [CrossRef]
- Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010, 10, 575–585. [Google Scholar] [CrossRef]
- Costa S, Ragusa MA, Lo Buglio G, Scilabra SD, Nicosia A. The Repertoire of Tissue Inhibitors of Metalloproteases: Evolution, Regulation of Extracellular Matrix Proteolysis, Engineering and Therapeutic Challenges. Life (Basel). 2022, 12, 1145. [Google Scholar] [CrossRef]
- Wang X, Khalil RA. Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. Adv Pharmacol. 2018, 81, 241–330. [Google Scholar] [CrossRef]
- Marchand M, Monnot C, Muller L, Germain S. Extracellular matrix scaffolding in angiogenesis and capillary homeostasis. Semin Cell Dev Biol. 2019, 89, 147–156. [Google Scholar] [CrossRef] [PubMed]
- Davis GE, Kemp SS. Extracellular Matrix Regulation of Vascular Morphogenesis, Maturation, and Stabilization. Cold Spring Harb Perspect Med. 2023, 13, a041156. [Google Scholar] [CrossRef] [PubMed]
- Kasravi M, Ahmadi A, Babajani A, Mazloomnejad R, Hatamnejad MR, Shariatzadeh S, Bahrami S, Niknejad H. Immunogenicity of decellularized extracellular matrix scaffolds: a bottleneck in tissue engineering and regenerative medicine. Biomater Res. 2023, 27, 10. [Google Scholar] [CrossRef]
- Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res. 2005, 97, 1093–1107. [Google Scholar] [CrossRef]
- Thomsen MS, Routhe LJ, Moos T. The vascular basement membrane in the healthy and pathological brain. J Cereb Blood Flow Metab. 2017, 37, 3300–3317. [Google Scholar] [CrossRef]
- Pozzi A, Yurchenco PD, Iozzo RV. The nature and biology of basement membranes. Matrix Biol. -58. [CrossRef]
- Mecham RP, Ramirez F. Extracellular Determinants of Arterial Morphogenesis, Growth, and Homeostasis. Curr Top Dev Biol. 2018, 130, 193–216. [Google Scholar] [CrossRef]
- Hill MA, Meininger GA. Arteriolar vascular smooth muscle cells: mechanotransducers in a complex environment. Int J Biochem Cell Biol. 2012, 44, 1505–1510. [Google Scholar] [CrossRef]
- Majesky MW, Weiser-Evans MCM. The adventitia in arterial development, remodeling, and hypertension. Biochem Pharmacol. 2022, 205, 115259. [Google Scholar] [CrossRef]
- Tinajero MG, Gotlieb AI. Recent Developments in Vascular Adventitial Pathobiology: The Dynamic Adventitia as a Complex Regulator of Vascular Disease. Am J Pathol. 2020, 190, 520–534. [Google Scholar] [CrossRef]
- Stenmark KR, Yeager ME, El Kasmi KC, Nozik-Grayck E, Gerasimovskaya EV, Li M, Riddle SR, Frid MG. The adventitia: essential regulator of vascular wall structure and function. Annu Rev Physiol. 2013, 75, 23–47. [Google Scholar] [CrossRef]
- Majesky MW, Dong XR, Hoglund V, Mahoney WM Jr, Daum G. The adventitia: a dynamic interface containing resident progenitor cells. Arterioscler Thromb Vasc Biol. 2011, 31, 1530–1539. [Google Scholar] [CrossRef] [PubMed]
- Eriksson, EE. Intravital microscopy on atherosclerosis in apolipoprotein e-deficient mice establishes microvessels as major entry pathways for leukocytes to advanced lesions. Circulation. 2011, 124, 2129–2138. [Google Scholar] [CrossRef] [PubMed]
- Maiellaro K, Taylor WR. The role of the adventitia in vascular inflammation. Cardiovasc Res. 2007, 75, 640–648. [Google Scholar] [CrossRef] [PubMed]
- Rademakers T, Douma K, Hackeng TM, Post MJ, Sluimer JC, Daemen MJ, Biessen EA, Heeneman S, van Zandvoort MA. Plaque-associated vasa vasorum in aged apolipoprotein E-deficient mice exhibit proatherogenic functional features in vivo. Arterioscler Thromb Vasc Biol. 2013, 33, 249–256. [Google Scholar] [CrossRef]
- Mazurek R, Dave JM, Chandran RR, Misra A, Sheikh AQ, Greif DM. Vascular Cells in Blood Vessel Wall Development and Disease. Adv Pharmacol. 2017, 78, 323–350. [Google Scholar] [CrossRef]
- Jain M, Chauhan AK. Role of Integrins in Modulating Smooth Muscle Cell Plasticity and Vascular Remodeling: From Expression to Therapeutic Implications. Cells. 2022, 11, 646. [Google Scholar] [CrossRef]
- Déglise S, Bechelli C, Allagnat F. Vascular smooth muscle cells in intimal hyperplasia, an update. Front Physiol. 2023, 13, 1081881. [Google Scholar] [CrossRef]
- Rifkin D, Sachan N, Singh K, Sauber E, Tellides G, Ramirez F. The role of LTBPs in TGF beta signaling. Dev Dyn. 2022, 251, 95–104. [Google Scholar] [CrossRef]
- Crisan M, Corselli M, Chen WC, Péault B. Perivascular cells for regenerative medicine. J Cell Mol Med. 2012, 16, 2851–2860. [Google Scholar] [CrossRef]
- Sluimer JC, Kolodgie FD, Bijnens AP, Maxfield K, Pacheco E, Kutys B, Duimel H, Frederik PM, van Hinsbergh VW, Virmani R, Daemen MJ. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol. 2009, 53, 1517–1527. [Google Scholar] [CrossRef]
- Wang M, Jiang L, Monticone RE, Lakatta EG. Proinflammation: the key to arterial aging. Trends Endocrinol Metab. 2014, 25, 72–79. [Google Scholar] [CrossRef] [PubMed]
- Wang M, Monticone RE, McGraw KR. Proinflammation, profibrosis, and arterial aging. Aging Med (Milton). 2020, 3, 159–168. [Google Scholar] [CrossRef] [PubMed]
- Cui N, Hu M, Khalil RA. Biochemical and Biological Attributes of Matrix Metalloproteinases. Prog Mol Biol Transl Sci. 2017, 147, 1–73. [Google Scholar] [CrossRef]
- Rienks M, Barallobre-Barreiro J, Mayr M. The Emerging Role of the ADAMTS Family in Vascular Diseases. Circ Res. 2018, 123, 1279–1281. [Google Scholar] [CrossRef] [PubMed]
- Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 2012, 110, 624–637. [Google Scholar] [CrossRef]
- Chen FM, Zhang M, Wu ZF. Toward delivery of multiple growth factors in tissue engineering. Biomaterials. 2010, 31, 6279–308. [Google Scholar] [CrossRef]
- Rouwkema J, Rivron NC, van Blitterswijk CA. Vascularization in tissue engineering. Trends Biotechnol. 2008, 26, 434–441. [Google Scholar] [CrossRef]
- Zou D, Zhang Z, He J, Zhang K, Ye D, Han W, Zhou J, Wang Y, Li Q, Liu X, Zhang X, Wang S, Hu J, Zhu C, Zhang W, zhou Y, Fu H, Huang Y, Jiang X. Blood vessel formation in the tissue-engineered bone with the constitutively active form of HIF-1α mediated BMSCs. Biomaterials. 2012, 33, 2097–2108. [Google Scholar] [CrossRef]
- Sun G, Shen YI, Kusuma S, Fox-Talbot K, Steenbergen CJ, Gerecht S. Functional neovascularization of biodegradable dextran hydrogels with multiple angiogenic growth factors. Biomaterials. 2011, 32, 95–106. [Google Scholar] [CrossRef]
- Bai Y, Bai L, Zhou J, Chen H, Zhang L. Sequential delivery of VEGF, FGF-2 and PDGF from the polymeric system enhance HUVECs angiogenesis in vitro and CAM angiogenesis. Cell Immunol. 2018, 323, 19–32. [Google Scholar] [CrossRef]
- Zamiri P, Masli S, Streilein JW, Taylor AW. Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci. 2006, 47, 3912–3918. [Google Scholar] [CrossRef] [PubMed]
- Hao X, Silva EA, Månsson-Broberg A, Grinnemo KH, Siddiqui AJ, Dellgren G, Wärdell E, Brodin LA, Mooney DJ, Sylvén C. Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res. 2007, 75, 178–185. [CrossRef]
- Chen RR, Silva EA, Yuen WW, Mooney DJ. Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res. 2007, 24, 258–264. [Google Scholar] [CrossRef] [PubMed]
- Nillesen ST, Geutjes PJ, Wismans R, Schalkwijk J, Daamen WF, van Kuppevelt TH. Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF2 and VEGF. Biomaterials. 2007, 28, 1123–1131. [Google Scholar] [CrossRef] [PubMed]
- Zieris A, Prokoph S, Levental KR, Welzel PB, Grimmer M, Freudenberg U, Werner C. FGF-2 and VEGF functionalization of starPEG-heparin hydrogels to modulate biomolecular and physical cues of angiogenesis. Biomaterials. 2010, 31, 7985–7994. [Google Scholar] [CrossRef]
- Hori Y, Ito K, Hamamichi S, Ozawa Y, Matsui J, Umeda IO, Fujii H. Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts. Anticancer Res. 2017, 37, 6629–6638. [Google Scholar] [CrossRef]
- Khan S, Villalobos MA, Choron RL, Chang S, Brown SA, Carpenter JP, Tulenko TN, Zhang P. Fibroblast growth factor and vascular endothelial growth factor play a critical role in endotheliogenesis from human adipose-derived stem cells. J Vasc Surg. 2017, 65, 1483–1492. [Google Scholar] [CrossRef]
- Gavard J, Patel V, Gutkind JS. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell. 2008, 14, 25–36. [Google Scholar] [CrossRef]
- Ngok SP, Geyer R, Liu M, Kourtidis A, Agrawal S, Wu C, Seerapu HR, Lewis-Tuffin LJ, Moodie KL, Huveldt D, Marx R, Baraban JM, Storz P, Horowitz A, Anastasiadis PZ. VEGF and Angiopoietin-1 exert opposing effects on cell junctions by regulating the Rho GEF Syx. J Cell Biol. 2012, 199, 1103–1115. [Google Scholar] [CrossRef]
- Anisimov A, Tvorogov D, Alitalo A, Leppänen VM, An Y, Han EC, Orsenigo F, Gaál EI, Holopainen T, Koh YJ, Tammela T, Korpisalo P, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Dejana E, Koh GY, Choi C, Saharinen P, Alitalo K. Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation. 2013, 127, 424–434. [Google Scholar] [CrossRef]
- Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Bråkenhielm E, Cao Y. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest. 2007, 117, 2766–2777. [Google Scholar] [CrossRef] [PubMed]
- Gianni-Barrera R, Di Maggio N, Melly L, Burger MG, Mujagic E, Gürke L, Schaefer DJ, Banfi A. Therapeutic vascularization in regenerative medicine. Stem Cells Transl Med. 2020, 9, 433–444. [Google Scholar] [CrossRef] [PubMed]
- Gianni-Barrera R, Burger M, Wolff T, Heberer M, Schaefer DJ, Gürke L, Mujagic E, Banfi A. Long-term safety and stability of angiogenesis induced by balanced single-vector co-expression of PDGF-BB and VEGF164 in skeletal muscle. Sci Rep. 2016, 6, 21546. [CrossRef]
- Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth factor delivery. Nat Biotechnol. 2001, 19, 1029–1034. [Google Scholar] [CrossRef]
- Banfi A, von Degenfeld G, Gianni-Barrera R, Reginato S, Merchant MJ, McDonald DM, Blau HM. Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB. FASEB J. 2012, 26, 2486–2497. [Google Scholar] [CrossRef]
- Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol. 2001, 12, 1448–1457. [Google Scholar] [CrossRef]
- Kupatt C, Hinkel R, Pfosser A, El-Aouni C, Wuchrer A, Fritz A, Globisch F, Thormann M, Horstkotte J, Lebherz C, Thein E, Banfi A, Boekstegers P. Cotransfection of vascular endothelial growth factor-A and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion role of vessel maturation. J Am Coll Cardiol. 2010, 56, 414–422. [Google Scholar] [CrossRef]
- Salmerón-Sánchez M, Dalby MJ. Synergistic growth factor microenvironments. Chem Commun (Camb). 2016, 52, 13327–13336. [Google Scholar] [CrossRef]
- Cao L, Arany PR, Wang YS, Mooney DJ. Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling. Biomaterials. 2009, 30, 4085–4093. [Google Scholar] [CrossRef]
- Ramirez F, Rifkin DB. Cell signaling events: a view from the matrix. Matrix Biol. 2003, 22, 101–107. [Google Scholar] [CrossRef]
- Martino MM, Tortelli F, Mochizuki M, Traub S, Ben-David D, Kuhn GA, Müller R, Livne E, Eming SA, Hubbell JA. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci Transl Med. 2011, 3, 100ra89. [Google Scholar] [CrossRef]
- Bray LJ, Binner M, Holzheu A, Friedrichs J, Freudenberg U, Hutmacher DW, Werner C. Multi-parametric hydrogels support 3D in vitro bioengineered microenvironment models of tumour angiogenesis. Biomaterials. 2015, 53, 609–620. [Google Scholar] [CrossRef] [PubMed]
- García JR, Clark AY, García AJ. Integrin-specific hydrogels functionalized with VEGF for vascularization and bone regeneration of critical-size bone defects. J Biomed Mater Res A. 2016, 104, 889–900, rratum in: J Biomed Mater Res A. 2016; 104(7): 1845. [Google Scholar] [CrossRef]
- Llopis-Hernández V, Cantini M, González-García C, Cheng ZA, Yang J, Tsimbouri PM, García AJ, Dalby MJ, Salmerón-Sánchez M. Material-driven fibronectin assembly for high-efficiency presentation of growth factors. Sci Adv. 2016, 2, e1600188. [Google Scholar] [CrossRef]
- Moulisová V, Gonzalez-García C, Cantini M, Rodrigo-Navarro A, Weaver J, Costell M, Sabater I Serra R, Dalby MJ, García AJ, Salmerón-Sánchez M. Engineered microenvironments for synergistic VEGF - Integrin signalling during vascularization. Biomaterials. 2017, 126, 61–74. [Google Scholar] [CrossRef] [PubMed]
- Shekaran A, García JR, Clark AY, Kavanaugh TE, Lin AS, Guldberg RE, García AJ. Bone regeneration using an alpha 2 beta 1 integrin-specific hydrogel as a BMP-2 delivery vehicle. Biomaterials. 2014, 35, 5453–5461. [Google Scholar] [CrossRef]
- Schneller M, Vuori K, Ruoslahti E. Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBO J. 1997, 16, 5600–5607. [Google Scholar] [CrossRef]
- Scaffidi AK, Petrovic N, Moodley YP, Fogel-Petrovic M, Kroeger KM, Seeber RM, Eidne KA, Thompson PJ, Knight DA. alpha(v)beta(3) Integrin interacts with the transforming growth factor beta (TGFbeta) type II receptor to potentiate the proliferative effects of TGFbeta1 in living human lung fibroblasts. J Biol Chem. 2004, 279, 37726–37733. [Google Scholar] [CrossRef]
- Mattila E, Pellinen T, Nevo J, Vuoriluoto K, Arjonen A, Ivaska J. Negative regulation of EGFR signalling through integrin-alpha1beta1-mediated activation of protein tyrosine phosphatase TCPTP. Nat Cell Biol. 2005, 7, 78–85. [Google Scholar] [CrossRef]
- Mattila E, Marttila H, Sahlberg N, Kohonen P, Tähtinen S, Halonen P, Perälä M, Ivaska J. Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase. BMC Cancer. 2010, 10, 7. [Google Scholar] [CrossRef]
- Monteiro A I, Kollmetz T, Malmström J. Engineered systems to study the synergistic signaling between integrin-mediated mechanotransduction and growth factors (Review). Biointerphases. 2018, 13, 06D302. [Google Scholar] [CrossRef]
- Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res. 2007, 100, 782–794. [Google Scholar] [CrossRef] [PubMed]
- Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007, 116, 1832–1844. [Google Scholar] [CrossRef] [PubMed]
- Nielsen LB, Grønholdt ML, Schroeder TV, Stender S, Nordestgaard BG. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol. 1997, 17, 905–911. [Google Scholar] [CrossRef]
- Bartels ED, Christoffersen C, Lindholm MW, Nielsen LB. Altered metabolism of LDL in the arterial wall precedes atherosclerosis regression. Circ Res. 2015, 117, 933–942. [Google Scholar] [CrossRef]
- Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017, 38, 2459–2472. [Google Scholar] [CrossRef]
- Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013, 34, 3478–3490a. [Google Scholar] [CrossRef]
- Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol. 1995, 15, 534–542. [Google Scholar] [CrossRef]
- Simons, M. Fibroblast growth factors: the keepers of endothelial normalcy. J Clin Invest. 2021, 131, e152716. [Google Scholar] [CrossRef]
- Chen PY, Qin L, Baeyens N, Li G, Afolabi T, Budatha M, Tellides G, Schwartz MA, Simons M. Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest. 2015, 125, 4514–4528. [Google Scholar] [CrossRef]
- Soehnlein, O. Multiple roles for neutrophils in atherosclerosis. Circ Res. 2012, 110, 875–888. [Google Scholar] [CrossRef] [PubMed]
- Soehnlein O, Lindbom L, Weber C. Mechanisms underlying neutrophil-mediated monocyte recruitment. Blood. 2009, 114, 4613–23. [Google Scholar] [CrossRef] [PubMed]
- Chevre R, Gonzalez-Granado JM, Megens RT, Sreeramkumar V, Silvestre-Roig C, Molina-Sanchez P, et al. . High-resolution imaging of intravascular atherogenic inflammation in live mice. Circ Res. 2014, 114, 770–9. [Google Scholar] [CrossRef] [PubMed]
- Sundd P, Gutierrez E, Koltsova EK, Kuwano Y, Fukuda S, Pospieszalska MK, Groisman A, Ley K. ’Slings’ enable neutrophil rolling at high shear. Nature. 2012, 488, 399–403. [Google Scholar] [CrossRef]
- Muller, WA. Getting leukocytes to the site of inflammation. Vet Pathol. 2013, 50, 7–22. [Google Scholar] [CrossRef]
- Sumagin R, Prizant H, Lomakina E, Waugh RE, Sarelius IH. LFA-1 and Mac-1 define characteristically different intralumenal crawling and emigration patterns for monocytes and neutrophils in situ. J Immunol. 2010, 185, 7057–7066. [Google Scholar] [CrossRef]
- Fan Z, McArdle S, Marki A, Mikulski Z, Gutierrez E, Engelhardt B, Deutsch U, Ginsberg M, Groisman A, Ley K. Neutrophil recruitment limited by high-affinity bent β2 integrin binding ligand in cis. Nat Commun. 2016, 7, 12658. [Google Scholar] [CrossRef]
- Barreiro O, Yanez-Mo M, Serrador JM, Montoya MC, Vicente-Manzanares M, Tejedor R, Furthmayr H, Sanchez-Madrid F. Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J Cell Biol. 2002, 157, 1233–1245. [Google Scholar] [CrossRef]
- Carman CV, Springer TA. A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J Cell Biol. 2004, 167, 377–388. [Google Scholar] [CrossRef]
- Barzilai S, Yadav SK, Morrell S, Roncato F, Klein E, Stoler-Barak L, Golani O, Feigelson SW, Zemel A, Nourshargh S, Alon R. Leukocytes Breach Endothelial Barriers by Insertion of Nuclear Lobes and Disassembly of Endothelial Actin Filaments. Cell Rep. 2017, 18, 685–699. [Google Scholar] [CrossRef]
- Sluiter TJ, van Buul JD, Huveneers S, Quax PHA, de Vries MR. Endothelial Barrier Function and Leukocyte Transmigration in Atherosclerosis. Biomedicines. 2021, 9, 328. [Google Scholar] [CrossRef]
- Nourshargh S, Hordijk PL, Sixt M. Breaching multiple barriers: leukocyte motility through venular walls and the interstitium. Nat Rev Mol Cell Biol. 2010, 11, 366–378. [Google Scholar] [CrossRef] [PubMed]
- Maas SL, Soehnlein O, Viola JR. Organ-Specific Mechanisms of Transendothelial Neutrophil Migration in the Lung, Liver, Kidney, and Aorta. Front Immunol. 2018, 9, 2739. [Google Scholar] [CrossRef] [PubMed]
- Salminen AT, Allahyari Z, Gholizadeh S, McCloskey MC, Ajalik R, Cottle RN, Gaborski TR, McGrath JL. In vitro Studies of Transendothelial Migration for Biological and Drug Discovery. Front Med Technol. 2020, 2, 600616. [Google Scholar] [CrossRef]
- Pezhman L, Tahrani A, Chimen M. Dysregulation of Leukocyte Trafficking in Type 2 Diabetes: Mechanisms and Potential Therapeutic Avenues. Front Cell Dev Biol. 2021, 9, 624184. [Google Scholar] [CrossRef]
- Groyer E, Caligiuri G, Laschet-Khallou J, Nicoletti A. Immunological aspects of atherosclerosis. Presse Med. 4: Pt2); (3. [CrossRef]
- Zernecke A, Winkels H, Cochain C, Williams JW, Wolf D, Soehnlein O, Robbins CS, Monaco C, Park I, McNamara CA, Binder CJ, Cybulsky MI, Scipione CA, Hedrick CC, Galkina EV, Kyaw T, Ghosheh Y, Dinh HQ, Ley K. Meta-Analysis of Leukocyte Diversity in Atherosclerotic Mouse Aortas. Circ Res. 2020, 127, 402–426. [Google Scholar] [CrossRef]
- Jessup W, Kritharides L. Metabolism of oxidized LDL by macrophages. Curr Opin Lipidol. 2000, 11, 473–481. [Google Scholar] [CrossRef]
- Sorci-Thomas MG, Thomas MJ. Microdomains, Inflammation, and Atherosclerosis. Circ Res. 2016, 118, 679–691. [Google Scholar] [CrossRef]
- Zuchtriegel G, Uhl B, Hessenauer ME, Kurz AR, Rehberg M, Lauber K, Krombach F, Reichel CA. Spatiotemporal expression dynamics of selectins govern the sequential extravasation of neutrophils and monocytes in the acute inflammatory response. Arterioscler Thromb Vasc Biol. 2015, 35, 899–910. [Google Scholar] [CrossRef]
- Nourshargh S, Alon R. Leukocyte migration into inflamed tissues. Immunity. 2014, 41, 694–707. [Google Scholar] [CrossRef]
- Poznyak AV, Nikiforov NG, Markin AM, Kashirskikh DA, Myasoedova VA, Gerasimova EV, Orekhov AN. Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis. Front Pharmacol. 2021, 11, 613780. [Google Scholar] [CrossRef] [PubMed]
- Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993, 268, 11811–11816. [Google Scholar] [CrossRef]
- Acton SL, Scherer PE, Lodish HF, Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem. 1994, 269, 21003–21009. [Google Scholar] [CrossRef]
- Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010, 464, 1357–1361. [Google Scholar] [CrossRef]
- Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004, 45, 993–1007. [Google Scholar] [CrossRef]
- Hashimoto K, Kataoka N, Nakamura E, Tsujioka K, Kajiya F. Oxidized LDL specifically promotes the initiation of monocyte invasion during transendothelial migration with upregulated PECAM-1 and downregulated VE-cadherin on endothelial junctions. Atherosclerosis. 2007, 194, e9–e17. [Google Scholar] [CrossRef]
- Brugger W, Kreutz M, Andreesen R. Macrophage colony-stimulating factor is required for human monocyte survival and acts as a cofactor for their terminal differentiation to macrophages in vitro. J Leukoc Biol. 1991, 49, 483–488. [Google Scholar] [CrossRef]
- Lehtonen A, Matikainen S, Miettinen M, Julkunen I. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation. J Leukoc Biol. 2002, 71, 511–519. [Google Scholar] [CrossRef]
- Davis GE, Thomas JS, Madden S. The alpha4beta1 integrin can mediate leukocyte adhesion to casein and denatured protein substrates. J Leukoc Biol. 1997, 62, 318–328. [Google Scholar] [CrossRef]
- Tedgui A, Mallat Z. Atherosclerotic plaque formation. Rev Prat. 1999, 49, 2081–2086. [Google Scholar]
- Zhang X, Sessa WC, Fernández-Hernando C. Endothelial Transcytosis of Lipoproteins in Atherosclerosis. Front Cardiovasc Med. 2018, 5, 130. [Google Scholar] [CrossRef] [PubMed]
- Kim KW, Ivanov S, Williams JW. Monocyte Recruitment, Specification, and Function in Atherosclerosis. Cells. 2020, 10, 15. [Google Scholar] [CrossRef]
- Bäck M, Yurdagul A Jr, Tabas I, Öörni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019, 16, 389–406. [Google Scholar] [CrossRef]
- Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, Määttä A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Ylä-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, Witztum JL. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature. 2018, 558, 301–306. [Google Scholar] [CrossRef]
- Mourouzis K, Siasos G, Oikonomou E, Zaromitidou M, Tsigkou V, Antonopoulos A, Bletsa E, Stampouloglou P, Vlasis K, Vavuranakis M, Tousoulis D. Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease. Lipids Health Dis. 2021, 20, 12. [Google Scholar] [CrossRef]
- Bennett MR, Sinha S, Owens GK. Vascular Smooth Muscle Cells in Atherosclerosis. Circ Res. 2016, 118, 692–702. [Google Scholar] [CrossRef]
- Llorente-Cortés V, Martínez-González J, Badimon L. LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000, 20, 1572–1579. [Google Scholar] [CrossRef]
- Saunders WB, Bayless KJ, Davis GE. MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J Cell Sci. 2005, 118, 2325–2340. [Google Scholar] [CrossRef]
- Bolshakov IN, Gornostaev LM, Fominykh OI, Svetlakov AV. Synthesis, Chemical and Biomedical Aspects of the Use of Sulfated Chitosan. Polymers (Basel). 2022, 14, 3431. [Google Scholar] [CrossRef]
- Tabas I, Bornfeldt KE. Macrophage Phenotype and Function in Different Stages of Atherosclerosis. Circ Res. 2016, 118, 653–667. [Google Scholar] [CrossRef]
- Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014, 114, 1852–1866. [Google Scholar] [CrossRef] [PubMed]
- Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003, 92, 827–839. [Google Scholar] [CrossRef] [PubMed]
- Kumar BV, Connors TJ, Farber DL. Human T Cell Development, Localization, and Function throughout Life. Immunity. 2018, 48, 202–213. [Google Scholar] [CrossRef] [PubMed]
- Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000, 102, 2919–2922. [Google Scholar] [CrossRef] [PubMed]
- Zhou X, Robertson AK, Hjerpe C, Hansson GK. Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol. 2006, 26, 864–870. [Google Scholar] [CrossRef]
- Zhou X, Robertson AK, Rudling M, Parini P, Hansson GK. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res. 2005, 96, 427–434. [Google Scholar] [CrossRef]
- Li J, Ley K. Lymphocyte migration into atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2015, 35, 40–49. [Google Scholar] [CrossRef]
- Foks AC, Lichtman AH, Kuiper J. Treating atherosclerosis with regulatory T cells. Arterioscler Thromb Vasc Biol. 2015, 35, 280–287. [Google Scholar] [CrossRef]
- Proto JD, Doran AC, Gusarova G, Yurdagul A Jr, Sozen E, Subramanian M, Islam MN, Rymond CC, Du J, Hook J, Kuriakose G, Bhattacharya J, Tabas I. Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution. Immunity. 2018, 49, 666–677. [Google Scholar] [CrossRef]
- Ley, K. Role of the adaptive immune system in atherosclerosis. Biochem Soc Trans. 2020, 48, 2273–2281. [Google Scholar] [CrossRef]
- MacRitchie N, Grassia G, Noonan J, Cole JE, Hughes CE, Schroeder J, Benson RA, Cochain C, Zernecke A, Guzik TJ, Garside P, Monaco C, Maffia P. The aorta can act as a site of naïve CD4+ T-cell priming. Cardiovasc Res. 2020, 116, 306–316. [Google Scholar]
- Matsumoto M, Shigeta A, Miyasaka M, Hirata T. CD43 plays both antiadhesive and proadhesive roles in neutrophil rolling in a context-dependent manner. J Immunol. 2008, 181, 3628–3635. [Google Scholar] [CrossRef]
- Nácher M, Blázquez AB, Shao B, Matesanz A, Prophete C, Berin MC, Frenette PS, Hidalgo A. Physiological contribution of CD44 as a ligand for E-Selectin during inflammatory T-cell recruitment. Am J Pathol. 2011, 178, 2437–2446. [Google Scholar] [CrossRef] [PubMed]
- Shulman Z, Cohen SJ, Roediger B, Kalchenko V, Jain R, Grabovsky V, Klein E, Shinder V, Stoler-Barak L, Feigelson SW, Meshel T, Nurmi SM, Goldstein I, Hartley O, Gahmberg CG, Etzioni A, Weninger W, Ben-Baruch A, Alon R. Transendothelial migration of lymphocytes mediated by intraendothelial vesicle stores rather than by extracellular chemokine depots. Nat Immunol. 2011, 13, 67–76. [Google Scholar] [CrossRef]
- Sage AP, Tsiantoulas D, Binder CJ, Mallat Z. The role of B cells in atherosclerosis. Nat Rev Cardiol. 2019, 16, 180–196. [Google Scholar] [CrossRef]
- Wang L, Tang C. Targeting Platelet in Atherosclerosis Plaque Formation: Current Knowledge and Future Perspectives. Int J Mol Sci. 2020, 21, 9760. [Google Scholar] [CrossRef]
- Magwenzi S, Woodward C, Wraith KS, Aburima A, Raslan Z, Jones H, McNeil C, Wheatcroft S, Yuldasheva N, Febbriao M, Kearney M, Naseem KM. Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade. Blood. 2015, 125, 2693–2703. [Google Scholar] [CrossRef]
- Bakogiannis C, Sachse M, Stamatelopoulos K, Stellos K. Platelet-derived chemokines in inflammation and atherosclerosis. Cytokine. 2019, 122, 154157. [Google Scholar] [CrossRef]
- Shevchuk O, Begonja AJ, Gambaryan S, Totzeck M, Rassaf T, Huber TB, Greinacher A, Renne T, Sickmann A. Proteomics: A Tool to Study Platelet Function. Int J Mol Sci. 2021, 22, 4776. [Google Scholar] [CrossRef]
- Barrett TJ, Schlegel M, Zhou F, Gorenchtein M, Bolstorff J, Moore KJ, Fisher EA, Berger JS. Platelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosis. Sci Transl Med. 2019, 11, eaax0481. [Google Scholar] [CrossRef]
- Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25, 677–686. [Google Scholar] [CrossRef] [PubMed]
- Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008, 13, 453–461. [Google Scholar] [CrossRef] [PubMed]
- Meza D, Shanmugavelayudam SK, Mendoza A, Sanchez C, Rubenstein DA, Yin W. Platelets modulate endothelial cell response to dynamic shear stress through PECAM-1. Thromb Res. 2017, 150, 44–50. [CrossRef]
- Tersteeg C, Heijnen HF, Eckly A, Pasterkamp G, Urbanus RT, Maas C, Hoefer IE, Nieuwland R, Farndale RW, Gachet C, de Groot PG, Roest M. FLow-induced PRotrusions (FLIPRs): a platelet-derived platform for the retrieval of microparticles by monocytes and neutrophils. Circ Res. 2014, 114, 780–791. [Google Scholar] [CrossRef]
- Baidžajevas K, Hadadi É, Lee B, Lum J, Shihui F, Sudbery I, Kiss-Tóth E, Wong SC, Wilson HL. Macrophage polarisation associated with atherosclerosis differentially affects their capacity to handle lipids. Atherosclerosis. 2020, 305, 10–18. [Google Scholar] [CrossRef]
- Busch M, Westhofen TC, Koch M, Lutz MB, Zernecke A. Dendritic cell subset distributions in the aorta in healthy and atherosclerotic mice. PLoS One. 2014, 9, e88452. [Google Scholar] [CrossRef]
- Choi JH, Do Y, Cheong C, Koh H, Boscardin SB, Oh YS, Bozzacco L, Trumpfheller C, Park CG, Steinman RM. Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves. J Exp Med. 2009, 206, 497–505. [Google Scholar] [CrossRef]
- Sichien D, Lambrecht BN, Guilliams M, Scott CL. Development of conventional dendritic cells: from common bone marrow progenitors to multiple subsets in peripheral tissues. Mucosal Immunol. 2017, 10, 831–844. [Google Scholar] [CrossRef]
- Liu J, Zhang X, Cheng Y, Cao X. Dendritic cell migration in inflammation and immunity. Cell Mol Immunol. 2021, 18, 2461–2471. [Google Scholar] [CrossRef]
- Tiberio L, Del Prete A, Schioppa T, Sozio F, Bosisio D, Sozzani S. Chemokine and chemotactic signals in dendritic cell migration. Cell Mol Immunol. 2018, 15, 346–352. [Google Scholar] [CrossRef]
- Wang L, Gao B, Wu M, Yuan W, Liang P, Huang J. Profiles of Immune Cell Infiltration in Carotid Artery Atherosclerosis Based on Gene Expression Data. Front Immunol. 2021, 12, 599512. [Google Scholar] [CrossRef] [PubMed]
- Han H, Du R, Cheng P, Zhang J, Chen Y, Li G. Comprehensive Analysis of the Immune Infiltrates and Aberrant Pathways Activation in Atherosclerotic Plaque. Front Cardiovasc Med. 2021, 7, 602345. [Google Scholar] [CrossRef] [PubMed]
- Cortenbach KRG, Morales Cano D, Meek J, Gorris MAJ, Staal AHJ, Srinivas M, Jolanda M de Vries I, Fog Bentzon J, van Kimmenade RRJ. Topography of immune cell infiltration in different stages of coronary atherosclerosis revealed by multiplex immunohistochemistry. Int J Cardiol Heart Vasc. 2022, 44, 101111. [Google Scholar] [CrossRef]
- Gotsman I, Sharpe AH, Lichtman AH. T-cell costimulation and coinhibition in atherosclerosis. Circ Res. 2008, 103, 1220–1231. [Google Scholar] [CrossRef]
- Britsch S, Langer H, Duerschmied D, Becher T. The Evolving Role of Dendritic Cells in Atherosclerosis. Int J Mol Sci. 2024, 25, 2450. [Google Scholar] [CrossRef]
- Young JL, Libby P, Schönbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost. 2002, 88, 554–67. [Google Scholar] [CrossRef]
- Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface. 2011, 8, 153–70. [Google Scholar] [CrossRef]
- Hynes, RO. The extracellular matrix: not just pretty fibrils. Science. 2009, 326, 1216–1219. [Google Scholar] [CrossRef]
- Paralkar VM, Vukicevic S, Reddi AH. Transforming growth factor beta type 1 binds to collagen IV of basement membrane matrix: implications for development. Dev Biol. 1991, 143, 303–308. [Google Scholar] [CrossRef]
- Martino MM, Briquez PS, Ranga A, Lutolf MP, Hubbell JA. Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc Natl Acad Sci U S A. 2013, 110, 4563–4568. [Google Scholar] [CrossRef]
- Martino MM, Hubbell JA. The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB J. 2010, 24, 4711–4721. [Google Scholar] [CrossRef]
- Wijelath ES, Rahman S, Namekata M, Murray J, Nishimura T, Mostafavi-Pour Z, Patel Y, Suda Y, Humphries MJ, Sobel M. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res. 2006, 99, 853–860. [Google Scholar] [CrossRef]
- Kricker JA, Towne CL, Firth SM, Herington AC, Upton Z. Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology. 2003, 144, 2807–2815. [Google Scholar] [CrossRef] [PubMed]
- Hallmann R, Zhang X, Di Russo J, Li L, Song J, Hannocks MJ, Sorokin L. The regulation of immune cell trafficking by the extracellular matrix. Curr Opin Cell Biol. 2015, 36, 54–61. [Google Scholar] [CrossRef] [PubMed]
- Friedl P, Mayor R. Tuning Collective Cell Migration by Cell-Cell Junction Regulation. Cold Spring Harb Perspect Biol. 2017, 9, a029199. [Google Scholar] [CrossRef]
- Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993, 4, 1317–1326. [Google Scholar] [CrossRef]
- Atanasova M, Whitty A. Understanding cytokine and growth factor receptor activation mechanisms. Crit Rev Biochem Mol Biol. 2012, 47, 502–530. [Google Scholar] [CrossRef]
- Rozario T, DeSimone DW. The extracellular matrix in development and morphogenesis: a dynamic view. Dev Biol. 2010, 341, 126–140. [Google Scholar] [CrossRef]
- Korpisalo P, Ylä-Herttuala S. Stimulation of functional vessel growth by gene therapy. Integr Biol (Camb). [CrossRef]
- Mussbacher M, Schossleitner K, Kral-Pointner JB, Salzmann M, Schrammel A, Schmid JA. More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis. Curr Atheroscler Rep. 2022, 24, 483–492. [Google Scholar] [CrossRef]
- Gimbrone MA Jr, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016, 118, 620–636. [Google Scholar] [CrossRef]
- Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011, 146, 873–887. [Google Scholar] [CrossRef] [PubMed]
- Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res. 2009, 37, 4587–4602. [Google Scholar] [CrossRef] [PubMed]
- Ortiz-Barahona A, Villar D, Pescador N, Amigo J, del Peso L. Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction. Nucleic Acids Res. 2010, 38, 2332–2345. [Google Scholar] [CrossRef] [PubMed]
- Semenza, GL. Regulation of vascularization by hypoxia-inducible factor 1. Ann N Y Acad Sci. 2009, 1177, 2–8. [Google Scholar] [CrossRef]
- Jain T, Nikolopoulou EA, Xu Q, Qu A. Hypoxia inducible factor as a therapeutic target for atherosclerosis. Pharmacol Ther. 2018, 183, 22–33. [Google Scholar] [CrossRef]
- Rajagopalan S, Olin J, Deitcher S, Pieczek A, Laird J, Grossman PM, Goldman CK, McEllin K, Kelly R, Chronos N. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation. 2007, 115, 1234–1243. [Google Scholar] [CrossRef]
- Kuan CY, Chen HR, Gao N, Kuo YM, Chen CW, Yang D, Kinkaid MM, Hu E, Sun YY. Brain-targeted hypoxia-inducible factor stabilization reduces neonatal hypoxic-ischemic brain injury. Neurobiol Dis. 2021, 148, 105200. [Google Scholar] [CrossRef]
- Nakashima M, Watanabe M, Nakano K, Uchimaru K, Horie R. Differentiation of Hodgkin lymphoma cells by reactive oxygen species and regulation by heme oxygenase-1 through HIF-1α. Cancer Sci. 2021, 112, 2542–2555. [CrossRef]
- Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, Nishigaki I. The vascular endothelium and human diseases. Int J Biol Sci. 2013, 9, 1057–1069. [Google Scholar] [CrossRef]
- Kalinin RE, Gryaznov SV, Nikiforov AA, Kamaev AA, Shvalb AP, Slepnev AA. Nitric oxide synthase and endothelin-1 gene polymorphism in lower limb chronic venous insufficiency. Pavlov I.P. Russian Medical Biological Heraldl. 2015, 16, 97–102. [CrossRef]
- Dow CA, Templeton DL, Lincenberg GM, Greiner JJ, Stauffer BL, DeSouza CA. Elevations in C-reactive protein and endothelin-1 system activity in humans. Life Sci. 2016, 159, 66–70. [Google Scholar] [CrossRef] [PubMed]
- Trinity JD, Barrett-O’Keefe Z, Ives SJ, Morgan G, Rossman MJ, Donato AJ, Runnels S, Morgan DE, Gmelch BS, Bledsoe AD, Richardson RS, Wray DW. Endogenous endothelin-1 and femoral artery shear rate: impact of age and implications for atherosclerosis. J Hypertens. 2016, 34, 266–273. [Google Scholar] [CrossRef] [PubMed]
- Shelest, BA. Peripheral vessel wall changes in hypertensive patients with gout. Ter Arkh. 2016, 88, 43–46. [Google Scholar] [CrossRef] [PubMed]
- Pavlides S, Gutierrez-Pajares JL, Katiyar S, Jasmin JF, Mercier I, Walters R, Pavlides C, Pestell RG, Lisanti MP, Frank PG. Caveolin-1 regulates the anti-atherogenic properties of macrophages. Cell Tissue Res. 2014, 358, 821–831. [Google Scholar] [CrossRef]
- Zborovskaya, I.B. , Galetskiy S.A., Komel’kov A.V. Microdomain forming proteins in oncogenesis. Advances in Molecular Oncology. 2016, 3, 16–29. [Google Scholar] [CrossRef]
- Engelberger RP, Limacher A, Kucher N, Baumann F, Silbernagel G, Benghozi R, Do DD, Willenberg T, Baumgartner I. Biological variation of established and novel biomarkers for atherosclerosis: Results from a prospective, parallel-group cohort study. Clin Chim Acta. 2015, 447, 16–22. [Google Scholar] [CrossRef]
- Rozenberg I, Sluka SH, Mocharla P, Hallenberg A, Rotzius P, Borén J, Kränkel N, Landmesser U, Borsig L, Lüscher TF, Eriksson EE, Tanner FC. Deletion of L-selectin increases atherosclerosis development in ApoE-/- mice. PLoS One. 2011, 6, e21675. [Google Scholar] [CrossRef]
- Skopec IS, Vezikova NN, Marusenko IM, Barysheva OY. , Malafeev AV, Malygin AN. Сorrelation of inflammation biomarkers with the traditional risk factors in patients with acute coronary syndrome. Rational Pharmacotherapy in Cardiology. 2016, 12, 166–170. [Google Scholar] [CrossRef]
- Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007, 27, 2292–2301. [Google Scholar] [CrossRef]
- Kitagawa K, Matsumoto M, Sasaki T, Hashimoto H, Kuwabara K, Ohtsuki T, Hori M. Involvement of ICAM-1 in the progression of atherosclerosis in APOE-knockout mice. Atherosclerosis. 2002, 160, 305–310. [Google Scholar] [CrossRef]
- Signorelli SS, Anzaldi M, Libra M, Navolanic PM, Malaponte G, Mangano K, Quattrocchi C, Di Marco R, Fiore V, Neri S. Plasma Levels of Inflammatory Biomarkers in Peripheral Arterial Disease: Results of a Cohort Study. Angiology. 2016, 67, 870–874. [Google Scholar] [CrossRef] [PubMed]
- Belokopytova IS, Moskaletz OV, Paleev FN, Zotova OV. The diagnostic value of adhesive molecules sICAM -1 and sVCAM-1 in ischemic heart disease. The Journal of Atherosclerosis and Dyslipidemias. 2013, 4, 62–65. [Google Scholar]
- Circulation Research Thematic Synopsis. Atherosclerosis. Circ Res 2013, 112, e118–e147. [CrossRef]
- Al-Ghurabi ME, Muhi AA, Al-Mudhafar DH. Vascular cell adhesion molecule-1 and endothelial leukocyte adhesion molecule-1 as markers of atherosclerosis of NIDDM. Amer J Life Sci 2015, 3, 22–26. [Google Scholar] [CrossRef]
- Bala G, Blykers A, Xavier C, Descamps B, Broisat A, Ghezzi C, Fagret D, Van Camp G, Caveliers V, Vanhove C, Lahoutte T, Droogmans S, Cosyns B, Devoogdt N, Hernot S. Targeting of vascular cell adhesion molecule-1 by 18F-labelled nanobodies for PET/CT imaging of inflamed atherosclerotic plaques. Eur Heart J Cardiovasc Imaging. 2016, 17, 1001–1008. [Google Scholar] [CrossRef]
- Ni W, Egashira K, Kitamoto S, Kataoka C, Koyanagi M, Inoue S, Imaizumi K, Akiyama C, Nishida KI, Takeshita A. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2001, 103, 2096–2101. [Google Scholar] [CrossRef]
- Tsai MK, Hsieh CC, Kuo HF, Lee MS, Huang MY, Kuo CH, Hung CH. Effect of prostaglandin I2 analogs on monocyte chemoattractant protein-1 in human monocyte and macrophage. Clin Exp Med. 2015, 15, 245–253. [Google Scholar] [CrossRef]
- Kim CH, Mitchell JB, Bursill CA, Sowers AL, Thetford A, Cook JA, van Reyk DM, Davies MJ. The nitroxide radical TEMPOL prevents obesity, hyperlipidaemia, elevation of inflammatory cytokines, and modulates atherosclerotic plaque composition in apoE-/- mice. Atherosclerosis. 2015, 240, 234–241. [Google Scholar] [CrossRef]
- Saitoh T, Kishida H, Tsukada Y, Fukuma Y, Sano J, Yasutake M, Fukuma N, Kusama Y, Hayakawa H. Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris. J Am Coll Cardiol. 2000, 35, 655–665. [Google Scholar] [CrossRef]
- Cybulsky MI, Cheong C, Robbins CS. Macrophages and Dendritic Cells: Partners in Atherogenesis. Circ Res. 2016, 118, 637–652. [Google Scholar] [CrossRef]
- Seshiah PN, Kereiakes DJ, Vasudevan SS, Lopes N, Su BY, Flavahan NA, Goldschmidt-Clermont PJ. Activated monocytes induce smooth muscle cell death: role of macrophage colony-stimulating factor and cell contact. Circulation. 2002, 105, 174–180. [Google Scholar] [CrossRef] [PubMed]
- Lind L, Siegbahn A, Lindahl B, Stenemo M, Sundström J, Ärnlöv J. Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip. Stroke. 2015, 46, 3340–3347. [Google Scholar] [CrossRef] [PubMed]
- Andrés V, Pello OM, Silvestre-Roig C. Macrophage proliferation and apoptosis in atherosclerosis. Curr Opin Lipidol. 2012, 23, 429–438. [Google Scholar] [CrossRef] [PubMed]
- Kan XH, Zhong XZ, Zhang WD, Shi CY. Increased circulating macrophage-colony stimulating factor and monocyte chemoattractant protein-1 are predictors of in-hospital events in Chinese patients with unstable angina pectoris. Int J. Clin Exper Pathology 2016, 9, 2021–2026. [Google Scholar]
- Brånén L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004, 24, 2137–42. [Google Scholar] [CrossRef]
- Kober F, Canault M, Peiretti F, Mueller C, Kopp F, Alessi MC, Cozzone PJ, Nalbone G, Bernard M. MRI follow-up of TNF-dependent differential progression of atherosclerotic wall-thickening in mouse aortic arch from early to advanced stages. Atherosclerosis. 2007, 195, e93–e99. [Google Scholar] [CrossRef]
- Chew M, Zhou J, Daugherty A, Eriksson T, Ellermann-Eriksen S, Hansen PR, Falk E. Thalidomide inhibits early atherogenesis in apoE-deficient mice. APMIS Suppl.
- Boesten LS, Zadelaar AS, van Nieuwkoop A, Gijbels MJ, de Winther MP, Havekes LM, van Vlijmen BJ. Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice. Cardiovasc Res. 2005, 66, 179–185. [Google Scholar] [CrossRef]
- Canault M, Peiretti F, Mueller C, Kopp F, Morange P, Rihs S, Portugal H, Juhan-Vague I, Nalbone G. Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis. 2004, 172, 211–218. [Google Scholar] [CrossRef]
- Prasad S, Tyagi AK, Aggarwal BB. Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases. Exp Biol Med (Maywood). 2016, 241, 783–799. [Google Scholar] [CrossRef]
- Weintraub WS, Harrison DG. C-reactive protein, inflammation and atherosclerosis: do we really understand it yet? Eur Heart J. 2000, 21, 958–960. [CrossRef]
- Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 9: 22;116 Suppl 6A. [CrossRef]
- Ikonomidis I, Lekakis J, Revela I, Andreotti F, Nihoyannopoulos P. Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. Eur Heart J. 2005, 26, 1618–1624. [Google Scholar] [CrossRef] [PubMed]
- Koenig, W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol. 2013, 168, 5126–5134. [Google Scholar] [CrossRef] [PubMed]
- Yu Q, Liu Z, Waqar AB, Ning B, Yang X, Shiomi M, Graham MJ, Crooke RM, Liu E, Dong S, Fan J. Effects of antisense oligonucleotides against C-reactive protein on the development of atherosclerosis in WHHL rabbits. Mediators Inflamm. 2014, 2014, 979132. [Google Scholar] [CrossRef]
- Cossette É, Cloutier I, Tardif K, DonPierre G, Tanguay JF. Estradiol inhibits vascular endothelial cells pro-inflammatory activation induced by C-reactive protein. Mol Cell Biochem. 2013, 373, 137–47. [Google Scholar] [CrossRef]
- Wang Q, Huo L, He J, Ding W, Su H, Tian D, Welch C, Hammock BD, Ai D, Zhu Y. Soluble epoxide hydrolase is involved in the development of atherosclerosis and arterial neointima formation by regulating smooth muscle cell migration. Am J Physiol Heart Circ Physiol. 2015, 309, H1894–H1903. [Google Scholar] [CrossRef]
- Wu MD, Atkinson TM, Lindner JR. Platelets and von Willebrand factor in atherogenesis. Blood. 2017, 129, 1415–1419. [Google Scholar] [CrossRef]
- Ricci C, Ferri N. Naturally occurring PDGF receptor inhibitors with potential anti-atherosclerotic properties. Vascul Pharmacol. 2015, 70, 1–7. [Google Scholar] [CrossRef]
- Lee MH, Kwon BJ, Koo MA, You KE, Park JC. Mitogenesis of vascular smooth muscle cell stimulated by platelet-derived growth factor-bb is inhibited by blocking of intracellular signaling by epigallocatechin-3-O-gallate. Oxid Med Cell Longev. 2013, 2013, 827905. [CrossRef]
- Sihvola, RK. Platelet-derived growth factor and proinflammatory cytokines in cardiac allograft arteriosclerosis. Academic dissertation. 2003, 1–64. [Google Scholar]
- Pope CA 3rd, Bhatnagar A, McCracken JP, Abplanalp W, Conklin DJ, O’Toole T. Exposure to Fine Particulate Air Pollution Is Associated With Endothelial Injury and Systemic Inflammation. Circ Res. 2016, 119, 1204–1214. [Google Scholar] [CrossRef]
- Chi H, Messas E, Levine RA, Graves DT, Amar S. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation. 2004, 110, 1678–1685. [Google Scholar] [CrossRef] [PubMed]
- von der Thüsen JH, Kuiper J, van Berkel TJ, Biessen EA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev. 2003, 55, 133–66. [Google Scholar] [CrossRef] [PubMed]
- Vicenová B, Vopálenský V, Burýšek L, Pospíšek M. Emerging role of interleukin-1 in cardiovascular diseases. Physiol Res. 2009, 58, 481–498. [Google Scholar] [CrossRef]
- Folco EJ, Sukhova GK, Quillard T, Libby P. Moderate hypoxia potentiates interleukin-1β production in activated human macrophages. Circ Res. 2014, 115, 875–883. [Google Scholar] [CrossRef]
- Pagano PJ, Gutterman DD. The adventitia: the outs and ins of vascular disease. Cardiovasc Res. 2007, 75, 636–639. [Google Scholar] [CrossRef]
- Edsfeldt A, Grufman H, Asciutto G, Nitulescu M, Persson A, Nilsson M, Nilsson J, Gonçalves I. Circulating cytokines reflect the expression of pro-inflammatory cytokines in atherosclerotic plaques. Atherosclerosis. 2015, 241, 443–449. [Google Scholar] [CrossRef]
- Nakai Y, Iwabuchi K, Fujii S, Ishimori N, Dashtsoodol N, Watano K, Mishima T, Iwabuchi C, Tanaka S, Bezbradica JS, Nakayama T, Taniguchi M, Miyake S, Yamamura T, Kitabatake A, Joyce S, Van Kaer L, Onoé K. Natural killer T cells accelerate atherogenesis in mice. Blood. 2004, 104, 2051–2059. [Google Scholar] [CrossRef]
- Aslanian AM, Chapman HA, Charo IF. Transient role for CD1d-restricted natural killer T cells in the formation of atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2005, 25, 628–632. [Google Scholar] [CrossRef]
- Voloshyna I, Littlefield MJ, Reiss AB. Atherosclerosis and interferon-γ: new insights and therapeutic targets. Trends Cardiovasc Med. 2014, 24, 45–51. [Google Scholar] [CrossRef]
- Harvey EJ, Ramji DP. Interferon-gamma and atherosclerosis: pro- or anti-atherogenic? Cardiovasc Res. 2005, 67, 11–20. [CrossRef]
- Tavakoli NN, Harris AK, Sullivan DR, Hambly BD, Bao S. Interferon-γ deficiency reduces neointimal formation in a model of endoluminal endothelial injury combined with atherogenic diet. Int J Mol Med. 2012, 30, 545–552. [Google Scholar] [CrossRef] [PubMed]
- Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002, 277, 49982–49988. [Google Scholar] [CrossRef] [PubMed]
- Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000, 105, 1049–1056. [Google Scholar] [CrossRef] [PubMed]
- Rigotti, A. Scavenger receptors and atherosclerosis. Biol Res. 2000, 33, 97–103. [Google Scholar] [CrossRef]
- Bowling FL, Rashid ST, Boulton AJ. Preventing and treating foot complications associated with diabetes mellitus. Nat Rev Endocrinol. 2015, 11, 606–616. [Google Scholar] [CrossRef]
- Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 1994, 93, 662–670. [Google Scholar] [CrossRef]
- Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med. 2002, 136, 54–71. [Google Scholar] [CrossRef]
- Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res. 2009, 105, 724–736. [Google Scholar] [CrossRef]
- Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002, 105, 788–793. [Google Scholar] [CrossRef]
- Karvinen H, Ylä-Herttuala S. New aspects in vascular gene therapy. Curr Opin Pharmacol. 2010, 10, 208–211. [Google Scholar] [CrossRef]
- Simons M, Ware JA. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov. 2003, 2, 863–871. [Google Scholar] [CrossRef] [PubMed]
- Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER; VIVA Investigators. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003, 107, 1359–1365. [Google Scholar] [CrossRef] [PubMed]
- Björkegren JLM, Lusis AJ. Atherosclerosis: Recent developments. Cell. 2022, 185, 1630–1645. [Google Scholar] [CrossRef] [PubMed]
- Herrmann J, Lerman LO, Rodriguez-Porcel M, Holmes DR Jr, Richardson DM, Ritman EL, Lerman A. Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc Res. 2001, 51, 762–766. [Google Scholar] [CrossRef]
- Kirichenko AK, Shulmin AV, Sharkova AF, Patlataya NN, Bolshakov, IN. Morphological Reconstruction of Main Arteries by Perivascular Implantation of Sulfated Chitosan in Experimental Atherosclerosis. Mod. Technol. Med. 2017, 9, 115–122. [Google Scholar] [CrossRef]
- Polignano R, Baggiore C, Falciani F, Restelli U, Troisi N, Michelagnoli S, Panigada G, Tatini S, Farina A, Landini G. Efficacy, safety and feasibility of intravenous iloprost in the domiciliary treatment of patients with ischemic disease of the lower limbs. Eur Rev Med Pharmacol Sci. 2016, 20, 3720–3726. [Google Scholar]
- Martel C, Li W, Fulp B, Platt AM, Gautier EL, Westerterp M, Bittman R, Tall AR, Chen SH, Thomas MJ, Kreisel D, Swartz MA, Sorci-Thomas MG, Randolph GJ. Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Invest. 2013, 123, 1571–1579. [Google Scholar] [CrossRef]
- Langheinrich AC, Michniewicz A, Bohle RM, Ritman EL. Vasa vasorum neovascularization and lesion distribution among different vascular beds in ApoE-/-/LDL-/- double knockout mice. Atherosclerosis. 2007, 191, 73–81. [Google Scholar] [CrossRef]
- Milasan A, Dallaire F, Mayer G, Martel C. Effects of LDL Receptor Modulation on Lymphatic Function. Sci Rep. 2016, 6, 27862. [Google Scholar] [CrossRef]
- Drozdz K, Janczak D, Dziegiel P, Podhorska M, Piotrowska A, Patrzalek D, Andrzejak R, Szuba A. Adventitial lymphatics and atherosclerosis. Lymphology. 2012, 45, 26–33. [Google Scholar]
- Kholová I, Dragneva G, Cermáková P, Laidinen S, Kaskenpää N, Hazes T, Cermáková E, Steiner I, Ylä-Herttuala S. Lymphatic vasculature is increased in heart valves, ischaemic and inflamed hearts and in cholesterol-rich and calcified atherosclerotic lesions. Eur J Clin Invest. 2011, 41, 487–497. [Google Scholar] [CrossRef] [PubMed]
- Kim H, Kataru RP, Koh GY. Regulation and implications of inflammatory lymphangiogenesis. Trends Immunol. 2012, 33, 350–356. [Google Scholar] [CrossRef] [PubMed]
- Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008, 8, 618–631. [Google Scholar] [CrossRef] [PubMed]
- Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Chimenti S, Landsman L, Abramovitch R, Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006, 124, 175–189. [Google Scholar] [CrossRef]
- Dimova I, Karthik S, Makanya A, Hlushchuk R, Semela D, Volarevic V, Djonov V. SDF-1/CXCR4 signalling is involved in blood vessel growth and remodelling by intussusception. J Cell Mol Med. 2019, 23, 3916–3926. [Google Scholar] [CrossRef]
- Dimova I, Karthik S, Makanya A, Hlushchuk R, Semela D, Volarevic V, Djonov V. SDF-1/CXCR4 signalling is involved in blood vessel growth and remodelling by intussusception. J Cell Mol Med. 2019, 23, 3916–3926. [Google Scholar] [CrossRef]
- Ochoa CD, Wu RF, Terada LS. ROS signaling and ER stress in cardiovascular disease. Mol Aspects Med. 2018, 63, 18–29. [Google Scholar] [CrossRef]
- Alencar GF, Owsiany KM, Karnewar S, Sukhavasi K, Mocci G, Nguyen AT, Williams CM, Shamsuzzaman S, Mokry M, Henderson CA, Haskins R, Baylis RA, Finn AV, McNamara CA, Zunder ER, Venkata V, Pasterkamp G, Björkegren J, Bekiranov S, Owens GK. Stem Cell Pluripotency Genes Klf4 and Oct4 Regulate Complex SMC Phenotypic Changes Critical in Late-Stage Atherosclerotic Lesion Pathogenesis. Circulation. 2020, 142, 2045–2059. [Google Scholar] [CrossRef]
- Pan H, Xue C, Auerbach BJ, Fan J, Bashore AC, Cui J, Yang DY, Trignano SB, Liu W, Shi J, Ihuegbu CO, Bush EC, Worley J, Vlahos L, Laise P, Solomon RA, Connolly ES, Califano A, Sims PA, Zhang H, Li M, Reilly MP. Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human. Circulation. 2020, 142, 2060–2075. [Google Scholar] [CrossRef]
- Lacolley P, Regnault V, Nicoletti A, Li Z, Michel JB. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res. 2012, 95, 194–204. [Google Scholar] [CrossRef]
- He C, Hu X, Weston TA, Jung RS, Sandhu J, Huang S, Heizer P, Kim J, Ellison R, Xu J, Kilburn M, Bensinger SJ, Riezman H, Tontonoz P, Fong LG, Jiang H, Young SG. Macrophages release plasma membrane-derived particles rich in accessible cholesterol. Proc Natl Acad Sci U S A. 2018, 115, E8499–E8508. [Google Scholar] [CrossRef]
- Butoi ED, Gan AM, Manduteanu I, Stan D, Calin M, Pirvulescu M, Koenen RR, Weber C, Simionescu M. Cross talk between smooth muscle cells and monocytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules. Biochim Biophys Acta. 2011, 1813, 2026–2035. [Google Scholar] [CrossRef] [PubMed]
- Gan AM, Pirvulescu MM, Stan D, Simion V, Calin M, Manduteanu I, Butoi E. Monocytes and smooth muscle cells cross-talk activates STAT3 and induces resistin and reactive oxygen species production [corrected]. J Cell Biochem. 2013, 114, 2273–2283. [CrossRef]
- Vijayagopal P, Glancy DL. Macrophages stimulate cholesteryl ester accumulation in cocultured smooth muscle cells incubated with lipoprotein-proteoglycan complex. Arterioscler Thromb Vasc Biol. 1996, 16, 1112–1121. [Google Scholar] [CrossRef] [PubMed]
- Weinert S, Poitz DM, Auffermann-Gretzinger S, Eger L, Herold J, Medunjanin S, Schmeisser A, Strasser RH, Braun-Dullaeus RC. The lysosomal transfer of LDL/cholesterol from macrophages into vascular smooth muscle cells induces their phenotypic alteration. Cardiovasc Res. 2013, 97, 544–552. [Google Scholar] [CrossRef]
- Newby AC, Zaltsman AB. Fibrous cap formation or destruction--the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc Res. 1999, 41, 345–360. [Google Scholar] [CrossRef]
- Lu Q, Yao Y, Hu Z, Hu C, Song Q, Ye J, Xu C, Wang AZ, Chen Q, Wang QK. Angiogenic Factor AGGF1 Activates Autophagy with an Essential Role in Therapeutic Angiogenesis for Heart Disease. PLoS Biol. 2016, 14, e1002529. [Google Scholar] [CrossRef]
- Zhang J, Kasim V, Xie YD, Huang C, Sisjayawan J, Dwi Ariyanti A, Yan XS, Wu XY, Liu CP, Yang L, Miyagishi M, Wu SR. Inhibition of PHD3 by salidroside promotes neovascularization through cell-cell communications mediated by muscle-secreted angiogenic factors. Sci Rep. 2017, 7, 43935. [Google Scholar] [CrossRef]
- Luo LL, Han JX, Wu SR, Kasim V. Intramuscular injection of sotagliflozin promotes neovascularization in diabetic mice through enhancing skeletal muscle cells paracrine function. Acta Pharmacol Sin. 2022, 43, 2636–2650. [Google Scholar] [CrossRef]
- Liu C, Han J, Marcelina O, Nugrahaningrum DA, Huang S, Zou M, Wang G, Miyagishi M, He Y, Wu S, Kasim V. Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia. J Med Chem. 2022, 65, 135–162. [Google Scholar] [CrossRef]
- Fallah A, Sadeghinia A, Kahroba H, Samadi A, Heidari HR, Bradaran B, Zeinali S, Molavi O. Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. Biomed Pharmacother. 2019, 110, 775–785. [Google Scholar] [CrossRef] [PubMed]
- Folkman, J. Endogenous angiogenesis inhibitors. APMIS. 2004, 112, 496–507. [Google Scholar] [CrossRef] [PubMed]
- Vasilyeva NY, Levdanskya AV, Kuznetsova BN, Skvortsova GP, Kazachenko AS, Djakovitch L, Pinel C. Russ. J. Bioorg. Chem. 2015, 41, 725. [CrossRef]
- Quiñones JP, Peniche H, Peniche C. Chitosan Based Self-Assembled Nanoparticles in Drug Delivery. Polymers (Basel). 2018, 10, 235. [Google Scholar] [CrossRef]
- Cheng Y, Xie Y, Shi L, Xing Y, Guo, S, Gao, Y, Liu Z, Yan S, Shi, B. Effects of rare earth-chitosan chelate on growth performance, antioxidative and immune function in broilers. Italian Journal of Animal Science. 2022, 21, 303–313. [Google Scholar] [CrossRef]
- Imam SS, Alshehri S, Altamimi MA, Almalki RKH, Hussain A, Bukhari SI, Mahdi WA, Qamar W. Formulation of Chitosan-Coated Apigenin Bilosomes: In Vitro Characterization, Antimicrobial and Cytotoxicity Assessment. Polymers (Basel). 2022, 14, 921. [Google Scholar] [CrossRef]
- Yu J, Ruan Q, Nie X, Yu L, Huang B. Synthetic CD47 antibody-chitosan/hyaluronic acid polyelectrolyte complex mediates targeted inhibition of atherosclerotic plaques by exogenous foam-like cells via the NLRP3 pathway. J Biomater Appl. 2020, 34, 1381–1394. [Google Scholar] [CrossRef]
- Nguyen MA, Wyatt H, Susser L, Geoffrion M, Rasheed A, Duchez AC, Cottee ML, Afolayan E, Farah E, Kahiel Z, Côté M, Gadde S, Rayner KJ. Delivery of MicroRNAs by Chitosan Nanoparticles to Functionally Alter Macrophage Cholesterol Efflux in Vitro and in Vivo. ACS Nano. 2019, 13, 6491–6505. [Google Scholar] [CrossRef]
- Yu J, Ruan Q, Nie X, Yu L, Huang B. Synthetic CD47 antibody-chitosan/hyaluronic acid polyelectrolyte complex mediates targeted inhibition of atherosclerotic plaques by exogenous foam-like cells via the NLRP3 pathway. Journal of Biomaterials Applications. 2020, 34, 1381–1394. [Google Scholar] [CrossRef]
- Liu Y, Liu D, Zhu L, Gan Q, Le X. Temperature-dependent structure stability and in vitro release of chitosan-coated curcumin liposome. Food Res Int. 2015, 74, 97–105. [Google Scholar] [CrossRef]
- Talbot CPJ, Plat J, Ritsch A, Mensink RP. Determinants of cholesterol efflux capacity in humans. Prog Lipid Res. 2018, 69, 21–32. [Google Scholar] [CrossRef] [PubMed]
- van Gils JM, Derby MC, Fernandes LR, Ramkhelawon B, Ray TD, Rayner KJ, Parathath S, Distel E, Feig JL, Alvarez-Leite JI, Rayner AJ, McDonald TO, O’Brien KD, Stuart LM, Fisher EA, Lacy-Hulbert A, Moore KJ. The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat Immunol. 2012, 13, 136–143. [Google Scholar] [CrossRef] [PubMed]
- Du WL, Xu ZR, Han XY, Xu YL, Miao ZG. Preparation, characterization and adsorption properties of chitosan nanoparticles for eosin Y as a model anionic dye. J Hazard Mater. 2008, 153, 152–156. [Google Scholar] [CrossRef] [PubMed]
- Rice JJ, Martino MM, De Laporte L, Tortelli F, Briquez PS, Hubbell JA. Engineering the regenerative microenvironment with biomaterials. Adv Healthc Mater. 2013, 2, 57–71. [Google Scholar] [CrossRef] [PubMed]
- Moulisová V, Gonzalez-García C, Cantini M, Rodrigo-Navarro A, Weaver J, Costell M, Sabater I Serra R, Dalby MJ, García AJ, Salmerón-Sánchez M. Engineered microenvironments for synergistic VEGF - Integrin signalling during vascularization. Biomaterials. 2017, 126, 61–74. [Google Scholar] [CrossRef]
- Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat Mater. 2009, 8, 15–23. [Google Scholar] [CrossRef]
- Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL, Gold JP, Simons M. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation. 1999, 100, 1865–1871. [Google Scholar] [CrossRef]
- Ruel M, Laham RJ, Parker JA, Post MJ, Ware JA, Simons M, Sellke FW. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg. 2002, 124, 28–34. [Google Scholar] [CrossRef]
- Barc P, Plonek T, Baczynska D, Radwanska A, Witkiewicz W, Halon A, Kupczynska-Markiewicz D, Strozecki L, Korta K, Skora J. A combination of VEGF165/HGF genes is more effective in blood vessels formation than ANGPT1/VEGF165 genes in an in vivo rat model. Int J Clin Exp Med 2016, 9, 12737–12744.
- Makarevich PI, Boldyreva MA, Gluhanyuk EV, Efimenko AY, Dergilev KV, Shevchenko EK, Sharonov GV, Gallinger JO, Rodina PA, Sarkisyan SS, Hu YC, Parfyonova YV. Enhanced angiogenesis in ischemic skeletal muscle after transplantation of cell sheets from baculovirus-transduced adipose-derived stromal cells expressing VEGF165. Stem Cell Res Ther. 2015, 6, 204. [CrossRef]
- Vemulapalli S, Patel MR, Jones WS. Limb ischemia: cardiovascular diagnosis and management from head to toe. Curr Cardiol Rep. 2015, 17, 611. [Google Scholar] [CrossRef]
- Cooke JP, Losordo DW. Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circ Res. 2015, 116, 1561–1578. [Google Scholar] [CrossRef]
- Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH; TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002, 359, 2053–2058. [Google Scholar] [CrossRef] [PubMed]
- Jazwa A, Florczyk U, Grochot-Przeczek A, Krist B, Loboda A, Jozkowicz A, Dulak J. Limb ischemia and vessel regeneration: Is there a role for VEGF? Vascul Pharmacol. 2016, 86, 18–30. [CrossRef]
- Curry CW, Sturgeon SM, O’Grady BJ, Yates A, Kjar A, Paige H, Mowery LS, Katdare KA, Patel R, Mlouk K, Stiefbold MR, Vafaie-Partin S, Kawabata A, McKee R, Moore-Lotridge S, Hawkes A, Kusunose J, Gibson-Corley KN, Schmeckpeper J, Schoenecker JG, Caskey CF, Lippmann ES. Growth factor free, peptide-functionalized gelatin hydrogel promotes arteriogenesis and attenuates tissue damage in a murine model of critical limb ischemia. Biomaterials. 2023, 303, 122397. [Google Scholar] [CrossRef]
- Patel ZS, Mikos AG. Angiogenesis with biomaterial-based drug- and cell-delivery systems. J Biomater Sci Polym Ed. 2004, 15, 701–726. [Google Scholar] [CrossRef]
- King WJ, Krebsbach PH. Growth factor delivery: how surface interactions modulate release in vitro and in vivo. Adv Drug Deliv Rev. 2012, 64, 1239–1256. [Google Scholar] [CrossRef]
- Nicosia A, Salamone M, Costa S, Ragusa MA, Ghersi G. Mimicking Molecular Pathways in the Design of Smart Hydrogels for the Design of Vascularized Engineered Tissues. Int J Mol Sci. 2023, 24, 12314. [Google Scholar] [CrossRef]
- Stamati K, Priestley JV, Mudera V, Cheema U. Laminin promotes vascular network formation in 3D in vitro collagen scaffolds by regulating VEGF uptake. Exp Cell Res. 2014, 327, 68–77. [Google Scholar] [CrossRef]
- Haggerty AE, Maldonado-Lasunción I, Oudega M. Biomaterials for revascularization and immunomodulation after spinal cord injury. Biomed Mater. 2018, 13, 044105. [Google Scholar] [CrossRef]
- Song HG, Rumma RT, Ozaki CK, Edelman ER, Chen CS. Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise. Cell Stem Cell. 2018, 22, 340–354. [Google Scholar] [CrossRef]
- Aravamudhan A, Ramos DM, Nip J, Subramanian A, James R, Harmon MD, Yu X, Kumbar SG. Osteoinductive small molecules: growth factor alternatives for bone tissue engineering. Curr Pharm Des. 2013, 19, 3420–3428. [Google Scholar] [CrossRef] [PubMed]
- Simón-Yarza T, Formiga FR, Tamayo E, Pelacho B, Prosper F, Blanco-Prieto MJ. Vascular endothelial growth factor-delivery systems for cardiac repair: an overview. Theranostics. 2012, 2, 541–552. [Google Scholar] [CrossRef] [PubMed]
- Kumagai M, Marui A, Tabata Y, Takeda T, Yamamoto M, Yonezawa A, Tanaka S, Yanagi S, Ito-Ihara T, Ikeda T, Murayama T, Teramukai S, Katsura T, Matsubara K, Kawakami K, Yokode M, Shimizu A, Sakata R. Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia. Heart Vessels. 2016, 31, 713–721. [Google Scholar] [CrossRef] [PubMed]
- Foster GA, Headen DM, González-García C, Salmerón-Sánchez M, Shirwan H, García AJ. Protease-degradable microgels for protein delivery for vascularization. Biomaterials. 2017, 113, 170–175. [Google Scholar] [CrossRef]
- Yao S, Yang Y, Wang X, Wang L. Fabrication and characterization of aligned fibrin nanofiber hydrogel loaded with PLGA microspheres. Macromol. Res. 2017, 25, 528–533. [Google Scholar] [CrossRef]
- Zhang J, Xia W, Liu P, Cheng Q, Tahirou T, Gu W, Li B. Chitosan modification and pharmaceutical/biomedical applications. Mar Drugs. 2010, 8, 1962–1987. [Google Scholar] [CrossRef]
- Fischbach C, Mooney DJ. Polymers for pro- and anti-angiogenic therapy. Biomaterials. 2007, 28, 2069–2076. [Google Scholar] [CrossRef]
- Murphy WL, Peters MC, Kohn DH, Mooney DJ. Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials. 2000, 21, 2521–2527. [Google Scholar] [CrossRef]
- Wang Z, Wang Z, Lu WW, Zhen W, Yang D, Peng S. Novel biomaterial strategies for controlled growth factor delivery for biomedical applications. NPG Asia Mater. 2017, 9, e435. [Google Scholar] [CrossRef]
- Ziegler J, Anger D, Krummenauer F, Breitig D, Fickert S, Guenther KP. Biological activity of recombinant human growth factors released from biocompatible bone implants. J Biomed Mater Res A. 2008, 86, 89–97. [Google Scholar] [CrossRef]
- Ehrbar M, Schoenmakers R, Christen EH, Fussenegger M, Weber W. Drug-sensing hydrogels for the inducible release of biopharmaceuticals. Nat Mater. 2008, 7, 800–804. [Google Scholar] [CrossRef] [PubMed]
- Masters, KS. Covalent growth factor immobilization strategies for tissue repair and regeneration. Macromol Biosci. 2011, 11, 1149–1163. [Google Scholar] [CrossRef] [PubMed]
- Martino MM, Briquez PS, Maruyama K, Hubbell JA. Extracellular matrix-inspired growth factor delivery systems for bone regeneration. Adv Drug Deliv Rev. 2015, 94, 41–52. [Google Scholar] [CrossRef]
- Naito Y, Shinoka T, Duncan D, Hibino N, Solomon D, Cleary M, Rathore A, Fein C, Church S, Breuer C. Vascular tissue engineering: towards the next generation vascular grafts. Adv Drug Deliv Rev. [CrossRef]
- Freeman I, Cohen S. The influence of the sequential delivery of angiogenic factors from affinity-binding alginate scaffolds on vascularization. Biomaterials. 2009, 30, 2122–2131. [Google Scholar] [CrossRef]
- Freeman I, Kedem A, Cohen S. The effect of sulfation of alginate hydrogels on the specific binding and controlled release of heparin-binding proteins. Biomaterials. 2008, 29, 3260–3268. [Google Scholar] [CrossRef]
- Phadke G, Hanna RM, Ferrey A, Torres EA, Singla A, Kaushal A, Kalantar-Zadeh K, Kurtz I, Jhaveri KD. Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration. Clin Kidney J. 2021, 14, 2158–2165. [Google Scholar] [CrossRef]
- Butt OI, Carruth R, Kutala VK, Kuppusamy P, Moldovan NI. Stimulation of peri-implant vascularization with bone marrow-derived progenitor cells: monitoring by in vivo EPR oximetry. Tissue Eng. 2007, 13, 2053–2061. [Google Scholar] [CrossRef]
- Wei Z, Schnellmann R, Pruitt HC, Gerecht S. Hydrogel Network Dynamics Regulate Vascular Morphogenesis. Cell Stem Cell. 2020, 27, 798–812. [Google Scholar] [CrossRef]
- Singh S, Wu BM, Dunn JC. The enhancement of VEGF-mediated angiogenesis by polycaprolactone scaffolds with surface cross-linked heparin. Biomaterials. 2011, 32, 2059–2069. [Google Scholar] [CrossRef]
- Levenberg S, Rouwkema J, Macdonald M, Garfein ES, Kohane DS, Darland DC, Marini R, van Blitterswijk CA, Mulligan RC, D’Amore PA, Langer R. Engineering vascularized skeletal muscle tissue. Nat Biotechnol. 2005, 23, 879–884. [Google Scholar] [CrossRef] [PubMed]
- Chen YC, Lin RZ, Qi H, Yang Y, Bae H, Melero-Martin JM, Khademhosseini A. Functional Human Vascular Network Generated in Photocrosslinkable Gelatin Methacrylate Hydrogels. Adv Funct Mater. 2012, 22, 2027–2039. [Google Scholar] [CrossRef] [PubMed]
- Santos MI, Fuchs S, Gomes ME, Unger RE, Reis RL, Kirkpatrick CJ. Response of micro- and macrovascular endothelial cells to starch-based fiber meshes for bone tissue engineering. Biomaterials. 2007, 28, 240–248. [Google Scholar] [CrossRef] [PubMed]
- Unger RE, Dohle E, Kirkpatrick CJ. Improving vascularization of engineered bone through the generation of pro-angiogenic effects in co-culture systems. Adv Drug Deliv Rev. 2015, 94, 116–125. [Google Scholar] [CrossRef]
- Banno K, Yoder MC. Tissue regeneration using endothelial colony-forming cells: promising cells for vascular repair. Pediatr Res. [CrossRef]
- Perets A, Baruch Y, Weisbuch F, Shoshany G, Neufeld G, Cohen S. Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. J Biomed Mater Res A. 2003, 65, 489–497. [Google Scholar] [CrossRef]
- Janse van Rensburg A, Davies NH, Oosthuysen A, Chokoza C, Zilla P, Bezuidenhout D. Improved vascularization of porous scaffolds through growth factor delivery from heparinized polyethylene glycol hydrogels. Acta Biomater. 2017, 49, 89–100. [Google Scholar] [CrossRef]
- Newman AC, Nakatsu MN, Chou W, Gershon PD, Hughes CC. The requirement for fibroblasts in angiogenesis: fibroblast-derived matrix proteins are essential for endothelial cell lumen formation. Mol Biol Cell. 2011, 22, 3791–3800. [Google Scholar] [CrossRef]
- Berthod F, Symes J, Tremblay N, Medin JA, Auger FA. Spontaneous fibroblast-derived pericyte recruitment in a human tissue-engineered angiogenesis model in vitro. J Cell Physiol. 2012, 227, 2130–2137. [Google Scholar] [CrossRef]
- Abdul Sisak MA, Louis F, Matsusaki M. In vitro fabrication and application of engineered vascular hydrogels. Polym. J. 2020, 52, 871–881. [Google Scholar] [CrossRef]
- Kaplanskaya IB, Glasko EN, Frank GA. Angiogenesis, intercellular contacts and stromal-parenchymal relationships in norm and pathology. Russian Journal of Oncology. 2005, 4, 53–57. [Google Scholar]
- Deepa R, Paul W, Anilkumar TV, Sharma CP. Differential Healing of Full Thickness Rabbit Skin Wound by Fibroblast Loaded Chitosan Sponge. Journal of Biomaterials and Tissue Engineering. 2013, 3, 261–272. [Google Scholar] [CrossRef]
- Sun H, Wang X, Hu X, Yu W, You C, Hu H, Han C. Promotion of angiogenesis by sustained release of rhGM-CSF from heparinized collagen/chitosan scaffolds. J Biomed Mater Res B Appl Biomater. 2012, 100, 788–798. [Google Scholar] [CrossRef]
- Wang PW, Liu JL, Zhang T. In vitro biocompatibility of electrospun chitosan/collagen scaffold. J Nanomaterials. 2013, 2013, 958172. [Google Scholar] [CrossRef]
- Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011, 3, a004952. [Google Scholar] [CrossRef]
- Thomas AM, Gomez AJ, Palma JL, Yap WT, Shea LD. Heparin-chitosan nanoparticle functionalization of porous poly(ethylene glycol) hydrogels for localized lentivirus delivery of angiogenic factors. Biomaterials. 2014, 35, 8687–8693. [Google Scholar] [CrossRef]
- Bolshakov IN, Shestakova LA, Kotikov AR, Kaptyuk GI. Experimental atherosclerosis in rats. Morphological reconstruction of the main artery wall with the polysaccharide biopolymers. Fundamental Research. 2013, 10, 557–563. [Google Scholar]
- Alavi M, Nokhodchi A. An overview on antimicrobial and wound healing properties of ZnO nanobiofilms, hydrogels, and bionanocomposites based on cellulose, chitosan, and alginate polymers. Carbohydr. Polym. 2020, 227, 115349–10. [Google Scholar] [CrossRef]
- Lee S, Valmikinathan CM, Byun J, Kim S, Lee G, Mokarram N, Pai SB, Um E, Bellamkonda RV, Yoon YS. Enhanced therapeutic neovascularization by CD31-expressing cells and embryonic stem cell-derived endothelial cells engineered with chitosan hydrogel containing VEGF-releasing microtubes. Biomaterials. 2015, 63, 158–167. [Google Scholar] [CrossRef]
- Hasan A, Khattab A, Islam MA, Hweij KA, Zeitouny J, Waters R, Sayegh M, Hossain MM, Paul A. Injectable Hydrogels for Cardiac Tissue Repair after Myocardial Infarction. Adv Sci (Weinh). 2015, 2, 1500122. [Google Scholar] [CrossRef]
- Vieira T, Carvalho Silva J, Botelho do Rego AM, Borges JP, Henriques C. Electrospun biodegradable chitosan based-poly(urethane urea) scaffolds for soft tissue engineering. Mater Sci Eng C Mater Biol Appl. 2019, 103, 109819. [Google Scholar] [CrossRef]
- Zhao N, Yue Z, Cui J, Yao Y, Song X, Cui B, Qi X, Han Z, Han ZC, Guo Z, He ZX, Li Z. IGF-1C domain-modified hydrogel enhances therapeutic potential of mesenchymal stem cells for hindlimb ischemia. Stem Cell Res Ther. 2019, 10, 129. [Google Scholar] [CrossRef] [PubMed]
- Rouwkema J, Khademhosseini A. Vascularization and Angiogenesis in Tissue Engineering: Beyond Creating Static Networks. Trends Biotechnol. 2016, 34, 733–745. [Google Scholar] [CrossRef] [PubMed]
- Alsop AT, Pence JC, Weisgerber DW, Harley BAC, Bailey RC. Photopatterning of vascular endothelial growth factor within collagen-glycosaminoglycan scaffolds can induce a spatially confined response in human umbilical vein endothelial cells. Acta Biomater. 2014, 10, 4715–4722. [Google Scholar] [CrossRef] [PubMed]
- Baker BM, Trappmann B, Stapleton SC, Toro E, Chen CS. Microfluidics embedded within extracellular matrix to define vascular architectures and pattern diffusive gradients. Lab Chip. 2013, 13, 3246–3252. [Google Scholar] [CrossRef]
- Miller JS, Stevens KR, Yang MT, Baker BM, Nguyen DH, Cohen DM, Toro E, Chen AA, Galie PA, Yu X, Chaturvedi R, Bhatia SN, Chen CS. Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. Nat Mater. 2012, 11, 768–774. [Google Scholar] [CrossRef]
- Zheng Y, Chen J, Craven M, Choi NW, Totorica S, Diaz-Santana A, Kermani P, Hempstead B, Fischbach-Teschl C, López JA, Stroock AD. In vitro microvessels for the study of angiogenesis and thrombosis. Proc Natl Acad Sci U S A. 2012, 109, 9342–9347. [Google Scholar] [CrossRef]
- Kirichenko АК, Patlataya NN, Sharkova АF, Pevnev АА, Kontorev КV, Bolshakov IN. Pathomorphism of limb major vessels in experimental atherogenic inflammation. The role of adventitial intimal relations (review). Modern Technol Med. 2017, 9, 162–173. [Google Scholar] [CrossRef]
- Bolshakov IN, Shestakova LA, Kotikov AR, Kaptyuk GI. Experimental atherosclerosis in rats. Morphological reconstruction of the main artery wall with the polysaccharide biopolymers. Fundamental Research. 2013, 10, 557–563. [Google Scholar]
- Bolshakov IN, Shestakova LA, Kotikov AR, Kaptyuk GI. Experimental atherogenic inflammation of the great arteries in rabbits. Minimally invasive technology for morphological reconstruction of the vascular wall in the early stages of atherogenesis. J. Fundamental Research. 2013, 8, 343–350. [Google Scholar]
- Blatchley MR, Gerecht S. Acellular implantable and injectable hydrogels for vascular regeneration. Biomed Mater. 2015, 10, 034001. [Google Scholar] [CrossRef]
- Mongiat M, Andreuzzi E, Tarticchio G, Paulitti A. Extracellular Matrix, a Hard Player in Angiogenesis. Int J Mol Sci. 2016, 17, 1822. [Google Scholar] [CrossRef]
- Navab M, Hough GP, Stevenson LW, Drinkwater DC, Laks H, Fogelman AM. Monocyte migration into the subendothelial space of a coculture of adult human aortic endothelial and smooth muscle cells. J Clin Invest. 1988, 82, 1853–1863. [Google Scholar] [CrossRef] [PubMed]
- Murphy SV, De Coppi P, Atala A. Opportunities and challenges of translational 3D bioprinting. Nat Biomed Eng. 2020, 4, 370–380. [Google Scholar] [CrossRef]
- Yang J, Dang H, Xu Y. Recent advancement of decellularization extracellular matrix for tissue engineering and biomedical application. Artif Organs. 2022, 46, 549–567. [Google Scholar] [CrossRef]
- Klingenberg R, Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J. 2009, 30, 2838–2844. [Google Scholar] [CrossRef]
- Ding X, Gao J, Wang Z, Awada H, Wang Y. A shear-thinning hydrogel that extends in vivo bioactivity of FGF2. Biomaterials. 2016, 111, 80–89. [CrossRef]
- Shahzadi L, Yar M, Jamal A, Siddiqi SA, Chaudhry AA, Zahid S, Tariq M, Rehman IU, MacNeil S. Triethyl orthoformate covalently cross-linked chitosan-(poly vinyl) alcohol based biodegradable scaffolds with heparin-binding ability for promoting neovascularisation. J Biomater Appl. 2016, 31, 582–593. [Google Scholar] [CrossRef]
- Yar M, Gigliobianco G, Shahzadi L, Dew L, Siddiqi SA, Khan AF, Chaudhry AA, Rehman I, MacNeil S. Production of chitosan PVA PCL hydrogels to bind heparin and induce angiogenesis. International Journal of Polymeric Materials and Polymeric Biomaterials. 2016, 65, 466–476. [Google Scholar] [CrossRef]
- Adrian E, Treľová D, Filová E, Kumorek M, Lobaz V, Poreba R, Janoušková O, Pop-Georgievski O, Lacík I, Kubies D. Complexation of CXCL12, FGF-2 and VEGF with Heparin Modulates the Protein Release from Alginate Microbeads. Int J Mol Sci. 2021, 22, 11666. [Google Scholar] [CrossRef]
- Jeon O, Lee K, Alsberg E. Spatial Micropatterning of Growth Factors in 3D Hydrogels for Location-Specific Regulation of Cellular Behaviors. Small. 2018, 14, e1800579. [Google Scholar] [CrossRef]
- Nilasaroya A, Kop AM, Morrison DA. Heparin-functionalized hydrogels as growth factor-signaling substrates. J Biomed Mater Res A. 2021, 109, 374–384. [Google Scholar] [CrossRef] [PubMed]
- Claaßen C, Sewald L, Tovar GEM, Borchers K. Controlled Release of Vascular Endothelial Growth Factor from Heparin-Functionalized Gelatin Type A and Albumin Hydrogels. Gels. 2017, 3, 35. [Google Scholar] [CrossRef]
- Lu Q, Li M, Zou Y, Cao T. Delivery of basic fibroblast growth factors from heparinized decellularized adipose tissue stimulates potent de novo adipogenesis. J Control Release. 2014, 174, 43–50. [Google Scholar] [CrossRef] [PubMed]
- Sheridan MH, Shea LD, Peters MC, Mooney DJ. Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery. J Control Release. [CrossRef]
- Zhang J, Li GP, Gao S, Yao Y, Pang LY, Li YJ, Wang WW, Zhao Q, Kong DL, Li C. Monocyte chemoattractant protein-1 released from polycaprolactone/chitosan hybrid membrane to promote angiogenesis in vivo. Journal of Bioactive and Compatible Polymers. 2014, 29, 572–588. [Google Scholar] [CrossRef]
- Obara K, Ishihara M, Fujita M, Kanatani Y, Hattori H, Matsui T, Takase B, Ozeki Y, Nakamura S, Ishizuka T, Tominaga S, Hiroi S, Kawai T, Maehara T. Acceleration of wound healing in healing-impaired db/db mice with a photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2. Wound Repair Regen. 2005, 13, 390–397. [CrossRef]
- Wang W, Lin S, Xiao Y, Huang Y, Tan Y, Cai L, Li X. Acceleration of diabetic wound healing with chitosan-crosslinked collagen sponge containing recombinant human acidic fibroblast growth factor in healing-impaired STZ diabetic rats. Life Sci. 2008, 82, 190–204. [Google Scholar] [CrossRef]
- Yoon JJ, Chung HJ, Lee HJ, Park TG. Heparin-immobilized biodegradable scaffolds for local and sustained release of angiogenic growth factor. J Biomed Mater Res A. 2006, 79, 934–942. [Google Scholar] [CrossRef]
- Wissink MJ, Beernink R, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J. Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices. J Control Release. 2000, 64, 103–114. [Google Scholar] [CrossRef]
- Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol. 1986, 128, 475–484. [Google Scholar] [CrossRef]
- Zhang L, Furst EM, Kiick KL. Manipulation of hydrogel assembly and growth factor delivery via the use of peptide-polysaccharide interactions. J Control Release. 2006, 114, 130–142. [Google Scholar] [CrossRef]
- Shen H, Hu X, Yang F, Bei J, Wang S. Cell affinity for bFGF immobilized heparin-containing poly(lactide-co-glycolide) scaffolds. Biomaterials. 2011, 32, 3404–3412. [Google Scholar] [CrossRef] [PubMed]
- Minardi S, Pandolfi L, Taraballi F, Wang X, De Rosa E, Mills ZD, Liu X, Ferrari M, Tasciotti E. Enhancing Vascularization through the Controlled Release of Platelet-Derived Growth Factor-BB. ACS Appl Mater Interfaces. 2017, 9, 14566–14575. [Google Scholar] [CrossRef]
- Kwee BJ, Budina E, Najibi AJ, Mooney DJ. CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials. 2018, 178, 109–121. [Google Scholar] [CrossRef] [PubMed]
- Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci. 2012, 37, 106–126. [Google Scholar] [CrossRef] [PubMed]
- Jain A, Gupta Y, Jain SK. Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J Pharm Pharm Sci. 2007, 10, 86–128. [Google Scholar]
- Silva EA, Mooney DJ. Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials. 2010, 31, 1235–1241. [Google Scholar] [CrossRef]
- Lee J, Bhang SH, Park H, Kim BS, Lee KY. Active blood vessel formation in the ischemic hindlimb mouse model using a microsphere/hydrogel combination system. Pharm Res. 2010, 27, 767–774. [Google Scholar] [CrossRef]
- Gonzalez-Pujana, A. , Orive G., Pedraz J.L., Santos-Vizcaino E., Hernandez R.M. Alginates and Their Biomedical Applications. Springer; Berlin/Heidelberg, Germany. Alginate Microcapsules for Drug Delivery. 2018; 67–100.
- Aparicio-Collado JL, García-San-Martín N, Molina-Mateo J, Torregrosa Cabanilles C, Donderis Quiles V, Serrano-Aroca A, Sabater I Serra R. Electroactive calcium-alginate/polycaprolactone/reduced graphene oxide nanohybrid hydrogels for skeletal muscle tissue engineering. Colloids Surf B Biointerfaces. 2022, 214, 112455. [Google Scholar] [CrossRef]
- Chu H, Johnson NR, Mason NS, Wang Y. A [polycation:heparin] complex releases growth factors with enhanced bioactivity. J Control Release. 2011, 150, 157–163. [Google Scholar] [CrossRef]
- Awada HK, Johnson NR, Wang Y. Dual delivery of vascular endothelial growth factor and hepatocyte growth factor coacervate displays strong angiogenic effects. Macromol Biosci. 2014, 14, 679–686. [Google Scholar] [CrossRef]
- Chu H, Chen CW, Huard J, Wang Y. The effect of a heparin-based coacervate of fibroblast growth factor-2 on scarring in the infarcted myocardium. Biomaterials. 2013, 34, 1747–1756. [Google Scholar] [CrossRef] [PubMed]
- Chu H, Gao J, Chen CW, Huard J, Wang Y. Injectable fibroblast growth factor-2 coacervate for persistent angiogenesis. Proc Natl Acad Sci U S A. 2011, 108, 13444–13449. [Google Scholar] [CrossRef] [PubMed]
- Lee KW, Johnson NR, Gao J, Wang Y. Human progenitor cell recruitment via SDF-1α coacervate-laden PGS vascular grafts. Biomaterials. 2013, 34, 9877–9885. [Google Scholar] [CrossRef] [PubMed]
- Johnson NR, Wang Y. Coacervate delivery systems for proteins and small molecule drugs. Expert Opin Drug Deliv. 2014, 11, 1829–1832. [Google Scholar] [CrossRef]
- Black KA, Priftis D, Perry SL, Yip J, Byun WY, Tirrell M. Protein Encapsulation via Polypeptide Complex Coacervation. ACS Macro Lett. 2014, 3, 1088–1091. [Google Scholar] [CrossRef]
- Oliveira MB, Ribeiro MP, Miguel SP, Neto AI, Coutinho P, Correia IJ, Mano JF. In vivo high-content evaluation of three-dimensional scaffolds biocompatibility. Tissue Eng Part C Methods. 2014, 20, 851–864. [Google Scholar] [CrossRef]
- Yu J, Gu Y, Du KT, Mihardja S, Sievers RE, Lee RJ. The effect of injected RGD modified alginate on angiogenesis and left ventricular function in a chronic rat infarct model. Biomaterials. 2009, 30, 751–756. [Google Scholar] [CrossRef]
- Rahman MS, Hasan MS, Nitai AS, Nam S, Karmakar AK, Ahsan MS, Shiddiky MJA, Ahmed MB. Recent Developments of Carboxymethyl Cellulose. Polymers (Basel). 2021, 13, 1345. [Google Scholar] [CrossRef]
- Silva CM, Ribeiro AJ, Ferreira D, Veiga F. Insulin encapsulation in reinforced alginate microspheres prepared by internal gelation. Eur J Pharm Sci. 2006, 29, 148–159. [Google Scholar] [CrossRef]
- Liu M, Zeng X, Ma C, Yi H, Ali Z, Mou X, Li S, Deng Y, He N. Injectable hydrogels for cartilage and bone tissue engineering. Bone Res. 2017, 5, 17014. [Google Scholar] [CrossRef]
- Bedian L, Villalba-Rodríguez AM, Hernández-Vargas G, Parra-Saldivar R, Iqbal HM. Bio-based materials with novel characteristics for tissue engineering applications - A review. Int J Biol Macromol. 2017, 98, 837–846. [Google Scholar] [CrossRef] [PubMed]
- Tang ZC, Liao WY, Tang AC, Tsai SJ, Hsieh PC. The enhancement of endothelial cell therapy for angiogenesis in hindlimb ischemia using hyaluronan. Biomaterials. 2011, 32, 75–86. [Google Scholar] [CrossRef] [PubMed]
- Grellier M, Bordenave L, Amédée J. Cell-to-cell communication between osteogenic and endothelial lineages: implications for tissue engineering. Trends Biotechnol. 2009, 27, 562–571. [Google Scholar] [CrossRef] [PubMed]
- Sun G, Shen YI, Ho CC, Kusuma S, Gerecht S. Functional groups affect physical and biological properties of dextran-based hydrogels. J Biomed Mater Res A. 2010, 93, 1080–1090. [Google Scholar] [CrossRef]
- DeQuach JA, Lin JE, Cam C, Hu D, Salvatore MA, Sheikh F, Christman KL. Injectable skeletal muscle matrix hydrogel promotes neovascularization and muscle cell infiltration in a hindlimb ischemia model. Eur Cell Mater. 2012, 23, 400–412. [Google Scholar] [CrossRef]
- Rao N, Agmon G, Tierney MT, Ungerleider JL, Braden RL, Sacco A, Christman KL. Engineering an Injectable Muscle-Specific Microenvironment for Improved Cell Delivery Using a Nanofibrous Extracellular Matrix Hydrogel. ACS Nano. 2017, 11, 3851–3859. [Google Scholar] [CrossRef]
- Tanihara M, Suzuki Y, Yamamoto E, Noguchi A, Mizushima Y. Sustained release of basic fibroblast growth factor and angiogenesis in a novel covalently crosslinked gel of heparin and alginate. J Biomed Mater Res. 2001, 56, 216–221. [Google Scholar] [CrossRef]
- Wissink MJ, Beernink R, Pieper JS, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J. Binding and release of basic fibroblast growth factor from heparinized collagen matrices. Biomaterials. 2001, 22, 2291–2299. [Google Scholar] [CrossRef]
- Lee KY, Peters MC, Anderson KW, Mooney DJ. Controlled growth factor release from synthetic extracellular matrices. Nature. 2000, 408, 998–1000. [Google Scholar] [CrossRef]
- Hong Y, Chen J, Fang H, Li G, Yan S, Zhang K, Wang C, Yin J. All-in-One Hydrogel Realizing Adipose-Derived Stem Cell Spheroid Production and In Vivo Injection via "Gel-Sol" Transition for Angiogenesis in Hind Limb Ischemia. ACS Appl Mater Interfaces. 2020, 12, 11375–11387. [Google Scholar] [CrossRef]
- Chen X, Aledia AS, Ghajar CM, Griffith CK, Putnam AJ, Hughes CC, George SC. Prevascularization of a fibrin-based tissue construct accelerates the formation of functional anastomosis with host vasculature. Tissue Eng Part A. 2009, 15, 1363–1371. [Google Scholar] [CrossRef] [PubMed]
- Armulik A, Genové G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011, 21, 193–215. [Google Scholar] [CrossRef] [PubMed]
- Greco Song HH, Rumma RT, Ozaki CK, Edelman ER, Chen CS. Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise. Cell Stem Cell. 2018, 22, 608. [Google Scholar] [CrossRef] [PubMed]
- Chandra P, Atala A. Engineering blood vessels and vascularized tissues: technology trends and potential clinical applications. Clin Sci (Lond). 2019, 133, 1115–1135. [Google Scholar] [CrossRef]
- Chang WG, Niklason LE. A short discourse on vascular tissue engineering. NPJ Regen Med. 2017, 2, 7. [Google Scholar] [CrossRef]
- Lovett M, Lee K, Edwards A, Kaplan DL. Vascularization strategies for tissue engineering. Tissue Eng Part B Rev. 2009, 15, 353–370. [Google Scholar] [CrossRef]
- Finking G, Hanke H. Nikolaj Nikolajewitsch Anitschkow (1885-1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis. 1997, 135, 1–7. [CrossRef]
- Cimato T, Beers J, Ding S, Ma M, McCoy JP, Boehm M, Nabel EG. Neuropilin-1 identifies endothelial precursors in human and murine embryonic stem cells before CD34 expression. Circulation. 2009, 119, 2170–2178. [Google Scholar] [CrossRef]
- Hou QP, De Bank PA, Shakesheff KM. Injectable scaffolds for tissue regeneration. J Mater Chem. 2004, 14, 1915–1923. [Google Scholar] [CrossRef]
- Mima Y, Fukumoto S, Koyama H, Okada M, Tanaka S, Shoji T, Emoto M, Furuzono T, Nishizawa Y, Inaba M. Enhancement of cell-based therapeutic angiogenesis using a novel type of injectable scaffolds of hydroxyapatite-polymer nanocomposite microspheres. PLoS One. 2012, 7, e35199. [Google Scholar] [CrossRef]
- Sakiyama-Elbert SE, Hubbell JA. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release. 2000, 65, 389–402. [Google Scholar] [CrossRef] [PubMed]
- Silva EA, Kim ES, Kong HJ, Mooney DJ. Material-based deployment enhances efficacy of endothelial progenitor cells. Proc Natl Acad Sci U S A. 2008, 105, 14347–14352. [Google Scholar] [CrossRef] [PubMed]
- Nomura Y, Sasaki Y, Takagi M, Narita T, Aoyama Y, Akiyoshi K. Thermoresponsive controlled association of protein with a dynamic nanogel of hydrophobized polysaccharide and cyclodextrin: heat shock protein-like activity of artificial molecular chaperone. Biomacromolecules. 2005, 6, 447–452. [Google Scholar] [CrossRef] [PubMed]
- Miyata T, Asami N, Uragami T. A reversibly antigen-responsive hydrogel. Nature. 1999, 399, 766–769. [Google Scholar] [CrossRef]
- Chen Y, Wang Z, Zhou L. Interleukin 8 inhibition enhanced cholesterol efflux in acetylated low-density lipoprotein-stimulated THP-1 macrophages. J Investig Med. 2014, 62, 615–620. [Google Scholar] [CrossRef]
- Doran AC, Yurdagul A Jr, Tabas I. Efferocytosis in health and disease. Nat Rev Immunol. 2020, 20, 254–267. [Google Scholar] [CrossRef]
- Gerlach BD, Ampomah PB, Yurdagul A Jr, Liu C, Lauring MC, Wang X, Kasikara C, Kong N, Shi J, Tao W, Tabas I. Efferocytosis induces macrophage proliferation to help resolve tissue injury. Cell Metab. 2021, 33, 2445–2463.e8. [Google Scholar] [CrossRef]
- Singh KP, Sharma AM. Critical limb ischemia: current approach and future directions. J Cardiovasc Transl Res. 2014, 7, 437–445. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).